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1 Introduction
Models of Care for Treatment of Adult Drug Misusers (NTA,
2002)1 – hereafter Models of Care 2002 – set out the national
framework for commissioning the treatment of adult drug
misusers in England, describing best practice in drug treatment
provision. The NTA has carried out two phases of extensive and
wide-ranging consultation (in 2004 and 2005) on an update of
Models of Care 2002, involving commissioners, service providers,
service users and other key stakeholders in the field. The resulting
updated document is Models of Care for Treatment of Adult Drug
Misusers: Update 2006 (hereafter Models of Care: Update 2006).
This update is intended to build on the framework and concepts
in Models of Care 2002 rather than replace them. It requires drug
treatment commissioners and providers to have implemented the
key tenets previously described in Models of Care 2002,
including: 
• The four-tiered model of commissioning
• Local screening and assessment systems
• The care planning and co-ordination of care at the heart of
structured drug treatment 
• The development of integrated care pathways.
This update is written in a similar format to Models of Care: Part 1
(2002), and is intended to fully replace it. Models of Care Part 2:
Full reference report (2002), summarises much of the evidence
base and is still relevant as a valuable reference source.
Models of Care: Update 2006 also incorporates the new strategy
to improve the quality and effectiveness of drug treatment. The
Treatment Effectiveness strategy, launched in 2006, has cross-
government approval and provides a greater focus on improving
clients’ journeys through more effective drug treatment and
reintegration into local communities (housing, education and
employment). The two main “units for improvement” for improving
treatment effectiveness are local commissioning partnerships and
the providers of drug treatment.
While the NTA does not have statutory responsibility regarding
drug treatment in prisons, the local primary care trusts do have
responsibility for commissioning clinical services. The National
Offender Management Service (NOMS) has committed to ensure
alignment of services and the implementation of relevant key
concepts from Models of Care: Update 2006 in prisons.
Models of Care: Update 2006 outlines:
• The policy context and rationale for updating Models of Care
2002
• The key differences between Models of Care 2002 and
Models of Care: Update 2006 
• The context of improving treatment effectiveness and
improving clients’ journeys 
• A reiteration of the four tiers 
• Updated information on assessment, care planning and
integrated care pathways 
• Definitions of the full range of treatment interventions in the
context of local treatment systems
• Draft quality requirements, which are in line with the NHS
policy and performance management structures 
• Key references.
This update should be viewed in the context of the NHS
Improvement Plan: Putting People at the Heart of Public Services
(2004)2 and the Department of Health’s (DH) Standards for Better
Health (2004).3 Models of Care: Update 2006 supports
development “standard D2”, described in Standards for Better
Health (2004), which will be used as the basis of Healthcare
Commission and NTA Improvement Reviews of drug treatment.
Implementing Models of Care: Update 2006 will contribute to the
Government’s Public Service Agreement (PSA) target to:
“…increase the participation of problem drug users in
drug treatment programmes by 55 per cent by 2004 and
by 100 per cent by 2008, and increase year on year the
proportion of users successfully sustaining or completing
treatment programmes.”
This final version of Models of Care: Update 2006 is accompanied
by a suite of documents, including:
• A separate report, Treating Drug Misuse Problems: Evidence
of Effectiveness (Gossop, 2006),4 reviews the current
evidence base. This is not included in detail in Models of Care:
Update 2006
• Additional linked guidance on care planning – Care Planning
Practice Guide (NTA, 2006)5
• A summary for service users and carers (due in summer
2006). 
Separate guidance, Models of Care for Treatment of Adult Alcohol
Misusers, is due for publication in 2006 following an extensive
consultation period. While there are important differences from
this document, the overall framework for commissioning
treatment services, the division into four tiers of interventions, the
description of levels of assessment that can be used and the
focus on effective co-ordination of care through care planning are
reiterated and remain consistent for both drug and alcohol
treatment service provision. Development of integrated care
pathways, high-quality commissioning and service delivery, in
response to assessments of need and consideration of evidence
for effective interventions, are also consistent between the two
documents.
6
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2 Policy and context
2.1 Good-quality drug treatment is effective
National and international evidence consistently shows that good-
quality drug treatment is highly effective in reducing illegal drug
misuse, improving the health of drug misusers, reducing drug-
related offending, reducing the risk of death due to overdose,
reducing the risk of death due to infections (including blood-borne
virus infections) and improving social functioning. Key references
for the effectiveness of drug treatment include the Taskforce
Review (Department of Health, 1996),6 the National Treatment
Outcome Research Study (1995–2000)7 and Treating Drug
Misuse Problems: Evidence of Effectiveness (NTA 2006).4
2.2 Significant improvement in access to 
and capacity in drug treatment since 2001
Funding for drug treatment has increased significantly since 2001
and has received substantial investment in the last five years. This
investment has achieved a rapid expansion in drug treatment to
achieve the Government’s PSA target to double the number of
drug misusers in effective, well-managed drug treatment by 2008.
The drug treatment workforce has also grown significantly, from
just over 6,000 practitioners and managers in 2002 to over
10,000 in March 2005.
The Audit Commission report Drug Misuse 2004,8 recognised the
impressive progress in the drug treatment system since 2002,
including the increased capacity of local drug treatment services,
better working partnerships between local agencies, and more
integrated services.
The wide variation in access to different types of treatment – as
referred to in an earlier Audit Commission report, Changing Habits
(2002)9 – has been largely tackled, with the implementation of
Models of Care 2002 leading to a good range of drug treatment
services now available in most areas in England.
In 2002, the Audit Commission reported drug treatment as being
characterised by lengthy waiting times in most areas. In
December 2001, the average national waiting time across all
types of treatment was 9.1 weeks. This had been reduced to a
national average of 2.3 weeks by June 2005. Furthermore, lower
average waiting times were achieved for all clients in intensive
Drug Interventions Programme (DIP) DAT areas (1.85 weeks in
June 2005).10
2.3 Drug treatment population trends
Data analysis from the National Drug Treatment Monitoring
System (NDTMS) for 2003/04 produced the following key findings
on clients in contact with structured drug treatment services.
• In 2003/04, 125,545 individuals were reported to the NDTMS
as receiving structured drug treatment. This figure has been
revised from the figure published in September 2004 after
resubmissions and corrections to the data received during
2004/05
• Heroin was identified as the main problem drug for over two-
thirds (67 per cent) of clients receiving drug treatment
• Where heroin was a client’s main drug of misuse, 21 per cent
reported crack or cocaine as the second drug of misuse
• Of clients reporting crack or cocaine as their main drug of
misuse, 13 per cent reported heroin as their second drug of
misuse
• Cannabis was reported as the main problem drug for clients
under 18 (61 per cent), while the figure for adults was nine per
cent. One-fifth (20 per cent) of individuals under 18 reported
heroin as their main problem drug, five per cent reported
crack or cocaine
• There are notable regional differences in the proportions of
individuals receiving drug treatment with crack or cocaine
recorded as the main problem drug. This ranges from under
two per cent of those treated in the NTA’s Yorkshire and
Humber region, to 23 per cent in the London region
• The most common referral route into treatment was self-
referral, representing over two-fifths (43 per cent) of all
reported referral sources
• Approximately 17 per cent of clients were referred into
treatment via criminal justice agencies
• Over half of all recorded drug treatment (54 per cent) was
reported as being through specialist prescribing programmes,
provided primarily by mental health trusts
• About half (52 per cent) of all clients discharged from
treatment remained in contact for 12 weeks or more following
a triage assessment
• A little under three-quarters (72 per cent) of clients presenting
were male
• Over two-fifths (41 per cent) of closed Tier 4 treatment
episodes resulted in a successful completion.
More information on the data analysis can be found in the report
Statistics from the National Drug Treatment Monitoring System
(NDTMS) 1 April 2003 to 31 March 2004 (DH, NTA, 2005).11 
Evidence also indicates that alcohol misuse among those in drug
treatment is common and polydrug and alcohol use is common, if
not the norm (Gossop, 2005).12 The National Treatment Outcome
Research Study (NTORS, 2000) found that drug treatment
services were having little or no impact on drug service users’
drinking behaviour, despite half having identified alcohol problems.
NTORS (1996) also commented on the “heavy burden” of health
problems carried by drug users attending treatment, which
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adversely affected their physical and mental health and was
accompanied by high rates of unemployment.
2.4 Harm reduction
Injecting behaviour. The latest Shooting Up report (2005)13 from
the Health Protection Agency (HPA) stated that needle and
syringe sharing increased in the late 1990s, and since then has
been relatively stable, but with drug users still reporting the
sharing of injecting equipment. A 2004 anonymous sample study
of injecting drug users (IDUs) in contact with drug agencies found
that 28 per cent shared needles or syringes in the previous four
weeks. However, sharing of other injecting equipment, such as
filters, spoons and flushing water, is more prevalent with 50 per
cent of current injectors reporting this in the same study. More
recent research (Rhodes, 2006)14 into drug injecting trends,
among those using heroin and crack or cocaine, suggests
growing risks of blood-borne virus (BBV) transmission, infections
and venous damage.
Hepatitis C. Shooting Up (2003),15 and the 200416 and 200513
updates, have also reported an increase in the prevalence of
hepatitis C infection among injecting drug users both in and out of
treatment. This has increased from 36 per cent in 1998 to 41 per
cent in 2003 (with only half of those hepatitis C seropositive being
aware of this). Furthermore, an increase in the incidence of
hepatitis C infection was reported among new injectors, indicating
that transmission is increasing. There are marked regional
variations in rates of hepatitis C infection among injecting drug
users, with prevalence rates of over 50 per cent found in London
and north-west England. Even higher rates have been seen in
treatment populations – Best et al (1999)17 found an 86 per cent
hepatitis C prevalence rate in one London drug treatment service.
Hepatitis B. In 2004, infection rates for hepatitis B virus of 21 per
cent were found among injecting drug users in England, Wales
and Northern Ireland. Infection rates among new injectors were
low, but had risen from five per cent in 1998 to nine per cent in
2003 (decreasing to 6.7 per cent in 2004). Increasing hepatitis B
vaccination rates were reported by samples of drug users, rising
from 25 per cent in 1998 to 54 per cent in 2004. 
HIV. Shooting Up (2005) reported a recent increase in the
prevalence of HIV infection among current IDUs in England.
Although HIV infection remains comparatively rare among IDUs
there are higher rates among IDUs in London, with around one in
25 infected. Although the numbers of IDUs infected elsewhere in
England are much lower, the 2004 prevalence rate (0.6 per cent)
is the highest seen outside London in this survey since 1993.
Site infections. Shooting Up (2005) noted continuing increases in
injecting site infections of various kinds, including tetanus and
wound botulism. This indicates both poor hygiene while injecting
and also some contaminated doses of drugs (particularly heroin).
Deaths related to drug misuse. The total number of deaths
related to drug misuse rose to 1,427 in 2004 (from 1,255 in
2003), the first increase since 2000 (ONS, 2006).18 Although the
number of deaths in 2004 was nine per cent lower than the
number in the baseline year of 1999, these deaths are
preventable and continued efforts should be made to reduce
these and avoid further increases.
A reinvigoration of harm reduction in all tiers of drug
treatment. These trends will require an immediate response from
both commissioners and providers to stem the increase of BBVs
and drug-related deaths among the drug-using population. Drug
treatment clearly also needs to be able to respond to the whole of
an individual’s pattern of substance misuse, including the misuse
of stimulants and alcohol.
2.5 Drug treatment and the criminal justice system
2.5.1 The Drug Interventions Programme
The Drug Interventions Programme (DIP) is a critical part of the
Government’s strategy for tackling drugs. DIP involves criminal
justice and drug treatment providers working together with other
services to provide a tailored solution for adults who commit
crime to fund their drug misuse. Its principal focus is to reduce
drug-related crime by engaging with problematic drug users and
moving them into appropriate drug treatment and support. It aims
to break the cycle of drug misuse and offending behaviour by
intervening at every stage of the criminal justice system to engage
offenders in drug treatment. Special measures for young people
are also being implemented. Delivery at a local level is through
drug action team partnerships, using criminal justice integrated
teams (CJITs) with a case management approach to offer access
to treatment and support. This begins at an offender’s first point
of contact with the criminal justice system, through custody,
court, sentencing and beyond, into resettlement.
2.5.2 The Drugs Act 2005 
New measures have been introduced under the 2005 Drugs
Act.19 These include “testing on arrest”, and “required
assessment” in all DIP-intensive areas in England, where
individuals testing positive for specified class A drugs, following
arrest or charge for “trigger offences”, will be required to attend an
initial assessment (known as a required assessment) of their drug
misuse. The aims of the new provisions are to identify more
problem drug users (by testing a larger sample of people) and to
encourage more people who test positive to attend assessment
(by adding a sanction of “failure to attend and remain – the
required assessment”). Testing on arrest for people arrested for a
trigger offence will enable adults misusing class A drugs to be
steered into treatment and away from crime earlier. It will increase
the volume of drug-misusing arrestees identified as having drug
8
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problems and will ensure that those who misuse drugs but are
not charged are also helped to engage in treatment.
Since 31 March 2006, Restriction on Bail has been “switched on”
in all local justice areas across England. This means that any adult
who appears before a court in England after testing positive for a
specified class A drug, in connection with the offence for which
they are charged, could be eligible for Restriction on Bail if they
reside in England. The restriction on bail provision provides an
opportunity to engage drug-misusing defendants with treatment,
by restricting access to court bail if they refuse a drug assessment
and any follow-up treatment proposed.
The above provisions only apply to those aged 18 or over.
Offenders will be faced with the choice of complying with what is
required of them or face criminal sanctions. The expectation is
that the majority of people will comply with the requirements
rather than risk prosecution.
2.5.3 Prison drug treatment
Prisons have a high concentration of problematic drug misusers
present in one place at any one time. There is an annual
throughflow of approximately 130,000 offenders and an average
of 84,500 drug-misusing prisoners may be in custody during the
course of a year – with around 49,000 present at any one time.
The drug treatment service framework is a core element of the
prison drug strategy and consists of clinical services, CARATs and
drug treatment programmes (rehabilitation programmes and
therapeutic communities). The range of drug interventions is
designed to meet the needs of prisoners with low, moderate and
severe drug misuse problems.
Clinical services for drug users in prison are described in Prison
Service Order 3550 (HMPS, 2000).20 Guidance on the
commissioning and delivery enhanced clinical services, covering a
range of Tier 3 prescribing interventions consistent with the
existing Department of Health clinical guidelines (Drug Misuse and
Dependence – Guidelines on Clinical Management (1999)21) is to
be published in 2006 by the Department of Health.22 This
guidance document will also represent part of a framework for the
joining together of clinical and CARAT teams in prison under an
integrated drug treatment system (see section 3.4).
2.6 Variation in the quality and 
effectiveness of drug treatment
There is a wide variation in the quality of drug treatment provision,
which can be seen in differences in the abilities of services to
retain clients. Analysis of treatment surveillance data (NTA/NDEC
2004)23 showed that clients attending one service in the north-
west of England were seven times more likely to drop out of
treatment than clients in a similar service in the same region.
The Audit Commission report Drug Misuse 20048 noted that
clients are often unsure about the goals of their treatment and are
not fully involved as active partners in treatment, for example
through lack of involvement in their care plans.
There is a wide variation in the quality of practice across the drug
treatment field. Forthcoming audit and research findings, from the
NTA and the NTA and Healthcare Commission Improvement
Reviews, will illustrate a wide variation in prescribing practice, care
planning, supervised consumption and needle exchange practice.
One of the intentions of Models of Care: Update 2006 is to
promote more consistently high-quality and effective treatment
practice.
A comprehensive review of counselling, assessment, referral,
advice and throughcare services (CARATs) undertaken between
2003 and 200524 mirrored the above findings. The consultation
process of the review found variations in the quality of CARATs
delivery working practices across the prison estate. As a result, a
CARAT practice manual has been developed which provides
workers with minimum agreed and accepted operational
guidelines for all component elements of the service.
The NTA has been working in collaboration with the Healthcare
Commission to develop a series of Improvement Reviews for
substance misuse treatment. These annual reviews will be used
to facilitate improvements in key aspects of drug treatment
services. The review process started in autumn 2005, focusing on
care planning and community prescribing interventions in
2005/06. In 2006/07, it will focus on commissioning and harm
reduction.
2.7 Improvements required in treatment effectiveness
Given the variable effectiveness of drug treatment services, this
update places a greater focus on the need to improve the
effectiveness of drug treatment systems. This includes improving
interventions to reduce the risk of blood-borne virus (BBV)
infection and the risk of overdose. It also focuses on the need to
improve engagement and retention in drug treatment, the
effectiveness of drug treatment delivery, and the reintegration into
communities of those completing treatment or being maintained
in treatment.
2.7.1 Treatment Effectiveness strategy
This update is also set in the context of the NTA’s Treatment
Effectiveness strategy, which identifies some of the critical
success factors to improving drug treatment and bases a delivery
plan for 2005–08 on them.25 The success factors fall into two
main groups:
• Improving clients’ journeys through treatment
• Improving local drug treatment systems.
9
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The strategy is designed to deliver a more dynamic treatment
system by focusing on the service user’s “treatment journey”,
together with a focus on individuals’ holistic needs (including
housing, education and employment) to maximise the benefits of
treatment. The key components of the strategy are:
Improving clients’ journeys through treatment
Waiting times. Since April 2006, the expectation will be that
service users voluntarily seeking treatment will be able to access
treatment within three weeks, with faster access for priority
groups. Partnerships will review any wait of six weeks or longer
and report to the local partnership and the NTA.
Retention. Retention in structured drug treatment has been built
into mainstream health performance management systems.
Retention targets are now built into primary care trusts’ local
delivery plans (LDPs) and are performance managed by strategic
health authorities. The Healthcare Commission ratings of mental
health trusts now include retention in treatment for 12 weeks.
Treatment delivery
Drug treatment should encourage and maximise the opportunities
for service users to achieve improvements in substance misuse,
health and social functioning, and reductions in crime and public
health risks. A critical factor to success in delivering improvements
in clients’ lifestyles is good care planning and frequent review of
care plans, with clients as partners in the process. All clients in
structured treatment should have an identifiable written care plan,
which tracks their progress and is regularly reviewed with them.
Improving treatment completion 
For clients who wish to be drug-free, treatment systems need to
be better configured to create better-planned exits from treatment
(including drug-related aftercare and support). 
Improvements in community integration
Whether clients wish to be maintained in the community on
substitute opioid medication or wish to be drug-free, drug
treatment systems should be well integrated with other systems
of care and social support, to provide opportunities for drug users
to receive appropriate housing, social support, education and
employment to maximise treatment gains and enable reintegration
into local communities.
Improving commissioning
The Treatment Effectiveness strategy identifies four critical
success factors that are considered important in improving local
commissioning partnerships: 
• Local commissioning partnerships linking plans with relevant
local strategic partnership groups 
• Better local needs assessments
• Development of local workforce strategies 
• Local commissioners who are competent and enabled to
performance manage drug treatment systems with clear
routes in, through and out of drug treatment.
Improving service provision
Four critical success factors that are considered important in
enabling drug treatment services in providing the highest quality
drug treatment are:
• Ensuring providers have a competent workforce
• Ensuring service providers can work with the diverse needs of
their service users
• Ensuring drug treatment is evidence based and underpinned
by good audit or clinical governance mechanisms
• Drug treatment services are managed using close to “real-
time” data.
For more detail on the NTA’s Treatment Effectiveness strategy, visit
the NTA website at www.nta.nhs.uk.
2.8 Changes to commissioning
2.8.1 Wider health policy context
Drug treatment commissioning is taking place within the context
of wider changes in the health and social care sector, where the
emphasis is now on the NHS moving from being a provider-driven
service to a commissioning-driven service. Currently, plans are
underway to review and reconfigure health bodies such as PCTs,
strategic health authorities and foundation trusts.26 The
Department of Health intends there to be a faster roll-out of
practice-based commissioning (PBC), where primary care
practices will be given more responsibility for commissioning
healthcare services.27 The intention is that primary care trusts
(PCTs) will continue to hold funds, but practices will be
responsible for assessing the health needs of local populations
and making commissioning decisions on appropriate services to
meet those needs. The timetable is set for all changes in the
system including reconfiguration of PCTs along local authority
boundaries, reconfiguration of strategic health authorities, and
universal implementation of PBC, by 2008.
In the longer term, commissioners will also have to be aware of,
and be able to respond effectively to, changes to the social care
system, as set out in the white paper Our Health, Our Care, Our
Say (DH, 2006).28
2.8.2 Drug treatment commissioning partnerships
There have already been changes in the commissioning of drug
treatment since 2002 and changes in the priority given to drug
treatment in health and criminal justice sectors. Drug treatment
has now been prioritised into mainstream health performance
management systems. A range of new local strategic
10
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partnerships for the planning of services have been developed.
Information systems have improved and resources for drug
treatment are planned to continue to increase until 2008.
2.8.3 Commissioning criminal justice services
PCTs are responsible for the commissioning of the healthcare
needs of local prison populations, including the clinical element of
drug treatment. The commissioning of drug treatment will be an
important consideration for prisons. Responsibility for
commissioning CARATs and prison drug treatment programmes
will soon fall to the new National Offender Management Service
(NOMS). Health performance management systems and PCT
commissioners will need to work in partnership with NOMS
wherever possible, to commission drug treatment for offenders.
Currently, commissioning for Drug Rehabilitation Requirements
(DRRs) in the community remains through the pooled treatment
budget. DRRs are community orders, which have been in force
since April 2005 and require the offender to have treatment to
reduce or eliminate their drug misuse and undergo drug testing.
2.8.4 A step-change in commissioning is required
In most local areas, commissioning drug treatment is a multi-
million pound business. In recognition of the complexity of the
task, a step-change is required to develop local commissioning
into local drug treatment systems management. Local drug
treatment systems have done well to develop in line with Models
of Care 2002. Now, Models of Care: Update 2006 calls for a
greater focus on service users’ journeys and “flow” through drug
treatment systems, and improvement in delivery of effective
pathways of care. This will require improved strategic partnerships
between health and criminal justice, as well as improved
partnerships with those responsible for housing, education and
employment services. Access to such mainstream provision is
vital for drug misusers in treatment, to maximise treatment gains
and prevent relapse into illegal drug misuse.
11
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3 Commissioning substance 
misuse services
3.1 A revised framework for drug treatment services
Models of Care 2002 outlined the four-tiered framework for
commissioning drug treatment. This was intended to provide a
conceptual framework and be applied to local areas with flexibility.
Implementation of the four-tiered framework has contributed in a
large part to ending the wide variation in access to different types
of treatment, so that each local area now has a broadly similar
basic range of drug treatment interventions.
The four-tiered framework has been well received and has
enabled a better articulation of provision of treatment. However,
the four tiers were a conceptual framework and were not
intended to be a rigid blueprint for provision. They have been
interpreted rather rigidly at times, with some unintended
consequences which need rectifying. It is important to note that
the tiers refer to the level of the interventions provided and do not
refer to the provider organisations (e.g. referring to a “Tier 3
agency” may not be appropriate as many agencies will need to
provide Tier 2 interventions alongside Tier 3 interventions).
3.2 Key differences between Models of Care 2002 
and Models of Care: Update 2006 
3.2.1 More focus on harm reduction with interventions
integrated into all tiers 
Feedback from consultation indicates that some harm reduction
activities have been marginalised into being provided only by what
have been called “Tier 2 services” (such as needle exchanges), at
a time when there is evidence that rates of BBV infection are
rising. Models of Care: Update 2006 advocates a far greater
emphasis on the need to reduce drug-related harm including risks
of BBV infection, overdose and other infections at all points in the
treatment journey, alongside other interventions and across a
range of tiers. Harm reduction interventions are required for drug
users before, during and after all structured drug treatment.
The term “harm reduction” can also cover a wide spectrum of
interventions. Models of Care: Update 2006 advocates the
commissioning and provision of a wide range of interventions to
reduce the adverse effects of drug misuse on drug users, with
particular focus on reducing the risk of immediate death due to
overdose and risks of morbidity and mortality due to BBVs and
other infections. This may include responses at a commissioning
and strategic planning level, and expansion and improvements in
the provision of interventions to reduce drug-related harm. The
latter may include increasing the availability of clean injecting
equipment, interventions to encourage drug injectors not to share
injecting equipment, to use ingestion methods as an alternative to
injecting, and to attract drug users into oral substitute treatment
when appropriate.
Widespread vaccination of drug users at risk of hepatitis B
infection is advocated and it is recommended that treatment
services encourage and enable clients already infected with BBVs
to take action to improve their health, reduce risks of transmission
of BBVs to others and link into appropriate medical services.
Initiatives that involve empowering service users or ex-users in
initiatives to reduce the risks of BBV infection and overdose,
through peer support or peer-led interventions, are generally
welcomed by service users.
Models of Care: Update 2006 also advocates a harm reduction
approach is adopted with local communities (e.g. minimising
discarded used injecting equipment) and service users’ families
and significant others (e.g. minimising risks to the children of
drug-misusing parents).
3.2.2 The four tiers revisited 
In Models of Care 2002, the four tiers were based upon a
combination of setting, interventions and the agency responsible
for providing the interventions. This has led to some differing
interpretations and particularly over-rigid interpretation. In Models
of Care: Update 2006, the tiers describe drug “interventions” and
the context for those interventions is described.
Providers spanning tiers
Some commissioners and providers have viewed community-
based agencies as delivering only one tier of interventions. Models
of Care 2002 clearly stated that an agency may provide
interventions from more than one tier, or a range of interventions
within a tier. Many community based specialised providers now,
appropriately, provide a range of interventions spanning Tier 2 and
Tier 3. This flexibility is welcomed.
More flexible opening times
With Tier 2 being classified as “open access”, there may also
have been a loss of focus on commissioning and providing flexible
access to some Tier 3 community structured interventions – the
majority of which are still only available during office hours. We
would welcome an extension of the opening hours of community-
based services to include evenings and weekends.
Tier 1 drug interventions and generic services
The emphasis in Models of Care: Update 2006 is that Tier 1
interventions are not the generic services themselves (e.g.
housing, social services). Rather, Tier 1 consists of a range of
drug-related interventions that can be provided by generic
providers depending on their competence and partnership
arrangements with specialised drug services. Given this change in
emphasis, interventions that were previously described as “Tier
4b” (e.g. care provided in inpatient hepatology units for drug users
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suffering from problems caused by hepatitis C infection) in Models
of Care 2002 are re-designated as Tier 1 in Models of Care:
Update 2006.
Tier 2 drug interventions
Consultation on Models of Care has suggested the need for a
wider recognition of the valuable role of open access Tier 2 drug
interventions that may just stop short of being classified as
structured drug treatment. In keeping with this, Models of Care:
Update 2006 advocates that Tier 2 interventions should be
strengthened. Within a local system, Tier 2 interventions should
include:
• Interventions to engage people into drug treatment 
• Interventions to support people prior to structured treatment 
• Interventions to help retain people in the treatment system
• A range of drug misuse harm reduction interventions
• Interventions to support active drug users who may not want
or need intensive structured drug treatment at that point in
their lives.
These interventions can include health interventions to meet
clients’ immediate health needs and a range of brief interventions
targeted at engaging clients in treatment. It is important that the
interventions are simple and can be provided quickly. Clients can
also be engaged in treatment through outreach services, which
can also seek to re-engage former service users who have
dropped out of treatment.
There is some perception that Tier 2 interventions have focused
solely on those who are still actively using illegal drugs. Models of
Care: Update 2006 recommends that Tier 2 open access
interventions should also be delivered to those who are drug-free
(and wish to remain so). Tier 2 interventions can be a component
of aftercare. Aftercare is described as:
• Drug-related support, such as relapse prevention, support
groups and individual support for those wishing to remain
drug-free, and access to user groups and advocacy
mechanisms (such as Narcotics Anonymous or equivalent)
• Non-drug-related support, such as access to education or
training, support from advisory services, helping develop
social networks and employment support.
Such aftercare follows the completion of care-planned drug
treatment.
It is expected that both interventions with an explicit abstinence
oriented approach and those that target active drug users are
commissioned locally. These interventions may be provided on
the same or different service sites. How these services are
delivered is a local treatment planning decision.
Community-based Tier 2 and Tier 3 interventions
Some consultation responses called for the creation of “tier two-
and-a-half”, in recognition of work that practitioners undertake
with clients that does not quite reach the threshold for care-
planned treatment (e.g. two or three “sessions” of brief
interventions). Rather than create a new tier, Models of Care:
Update 2006 advocates a more careful consideration of whether
Tier 2 or Tier 3 interventions are being provided and a recognition
that providers can and do provide a range of interventions at
different tiers.
The main difference between Tier 2 and Tier 3 interventions is that
Tier 3 refers to the provision of care-planned interventions that
meet the threshold for structured drug treatment, determined
following comprehensive assessment. The definitions of care
planning and of the various forms of structured treatment have
been amended and updated to aid clarity in Models of Care:
Update 2006. There are additional reporting requirements for Tier
3 interventions, including the completion of National Drug
Treatment Monitoring System (NDTMS) returns.
It is recognised that, in reality, the differences in some cases
between more structured forms of Tier 2 support and simpler
forms of Tier 3 interventions can be subtle. While care planning is
a requirement of structured treatment, it can also be used, if
appropriate, for some Tier 2 interventions (e.g. planned brief
motivational interventions). Some brief interventions, for example
for alcohol or cannabis use, may be provided in both tiers. In this,
and other equivocal cases, it will be the degree of structure of the
care plan and of the treatment intervention that will usually be the
best guide to determine the tier of intervention being provided. If a
service provider is delivering care-planned structured treatment
following comprehensive assessment, the interventions provided
should be classified as Tier 3.
Tier 2 interventions may not require the same degree of
commitment from the client. The level of assessment may be
lower (although there may be some). Tier 2 interventions may not
require the same degree of consent as for a planned course of
treatment and they often will not have the same level of duty of
care for the practitioner (though they should still carry some).
Therefore, there are different reporting requirements. Care plans
should be used, if appropriate, for Tier 2 interventions.
To maximise engagement and motivation following assessment,
all DATs and CJITs have been funded to build Tier 2 treatment
capacity to facilitate access to structured drug treatment.
If a service provider is providing care-planned care following
comprehensive assessment, the interventions provided should be
classified as Tier 3. Tier 3 interventions comprise care-planned
treatment, where an individual assessed has been found in need
of structured treatment and has a care plan, which involves the
client consenting to treatment. The client then receives drug
treatment and other interventions (sequentially or concurrently)
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according to the care plan drawn up with the keyworker, together
with scheduled keyworking sessions, and any co-ordination of
care or case management required.
The most appropriate guide to deciding whether interventions are
Tier 2 or Tier 3 is whether interventions are provided in the
context of a comprehensive care plan, following a comprehensive
assessment. Models of Care: Update 2006 contains a range of
definitions to help clarify the process of decision making, including
care planning, keyworking, the treatment interventions and how
they fit together.
All substitute prescribing interventions are Tier 3
Clinical experience, supported by consultation responses, has
indicated that all substitute prescribing interventions, including
those previously described as “low threshold” in Models of Care
2002, should be redefined as Tier 3 interventions, including those
delivered by prison healthcare This is because they require
comprehensive assessment, should be care planned and carry a
high duty of care for the clinician prescribing controlled drugs.
3.3 The Drug Interventions Programme (DIP)
The Drug Interventions Programme (DIP) provides an enhanced
Tier 2 service by offering the client ongoing support, through the
case management arrangements, in order to facilitate
engagement in structured treatment.
One of the key drivers for the development of the DIP was the
need to bridge the gap between assessment and referral from the
criminal justice system and effective engagement into structured
treatment. Evidence from the arrest referral scheme evaluations
(July 2002) consistently recorded high levels of attrition for clients
referred to drug treatment from the criminal justice system, with
an engagement rate of 20–25 per cent.
Criminal justice integrated teams (CJITs) are the key local delivery
mechanism of the DIP. They are established by the DATs as multi-
agency partnerships, comprising members from a range of
disciplines with a range of competences and skills. There is no
one model but a typical team might include drug workers based
in police custody suites or courts; case managers; those with
specialist knowledge of housing issues, mental health, education,
training and employment, and family support; outreach workers
working in the community, and dedicated prolific and persistent
offender (PPO) case managers.
Improving continuity of care for the individual is reliant upon
seamless case management through the effective provision and
communication of the right information at the right time to the
right people, throughout the “journey” of the drug misuser. Case
management should reflect the key elements of keyworking and
care planning. This process is facilitated through the use of the
Drug Interventions Record (DIR) by CJIT workers in the
community and CARATS or healthcare in prisons. The DIR has
three main roles. They are:
• To facilitate and improve standards of continuity of care for
drug users, and minimise duplication of assessments,
especially when they are moving between custody and
community but also when information is passed between
case managers and/or treatment providers
• To support the monitoring and research functions around the
Drug Interventions Programme, in line with the programme’s,
and other related, Performance Management Frameworks
• To be the form on which substance misuse triage assessment
is recorded in prison, whether or not the individual agrees to
the sharing of information with the CJIT for continuity of care
purposes.
Where a client is assessed by a CJIT worker following a triage
level assessment, the worker will use the DIR to record the
summary and outcomes from the assessment. Where clients
require structured treatment, they will be taken onto the CJIT
caseload and allocated a case manager or keyworker. Initial care
plans are then agreed with clients to identify what steps need to
be taken to engage them in treatment and what support can be
provided in the interim. This might involve ongoing contact with
the case manager to maintain the client’s motivation and address
social support needs, such as housing, employment and training.
The transition to structured treatment (Tier 3) is achieved when a
comprehensive assessment, followed by a full care plan, is
completed by the treatment provider. The CJIT worker who is the
case manager, with the client’s informed consent, can contribute
to this process and will continue to work with the client until they
are actively engaged in treatment with the Tier 3 provider.
3.4 Drug treatment based in prisons
A comprehensive framework of drug treatment services, spanning
Tiers 1–4, should be available in prisons to address the varying
needs of drug misusers. In principle, delivery of drug treatment in
prisons is very similar to providing treatment in the community.
However, there are specific factors that need to be taken into
account, given the different environment in which prison treatment
is provided.
As with any drug treatment, prisoners must be provided with
continuity of care both in custody and on release. It is vital that
any drug treatment, especially relapse prevention and release
planning, takes into account the differences that exist within
prison and community environments, in order to best prepare
prisoners for release.
There are three main types of drug treatment within prisons.
14
models of care drugs.qxp  03/07/2006  11:17  Page 14
Models of care for treatment of adult drug misusers: Update 2006
3.4.1 Clinical services
There is currently a range of clinical services (Tiers 2, 3 and 4)
available to:
• Provide appropriate clinical management of substance misuse
problems in all local (remand) prisons
• Address the associated wider health issues, which arise from
drug use, such as blood-borne viruses, deep vein
thromboses, abscesses and dental disease
• Engage in the care programme approach (CPA) to those
substance users with serious mental health problems (dual
diagnosis).
3.4.2 CARAT services
CARAT (counselling, assessment, referral, advice and
throughcare) services are available in all prisons holding those
over the age of 18 and provide Tier 2 and Tier 3 treatment.
CARAT services use a keyworking role, working with prison
clinical services, community treatment providers and others as
appropriate. The CARAT service will:
• Build on previous assessments of the individuals’ needs
• Provide a range of psychosocial support and interventions
• Refer to drug treatment programmes in custody where these
are available and appropriate, and maintain contact while the
client is participating in these programmes
• Build and maintain effective throughcare arrangements with
drug service providers in the community – through CJITs
where appropriate.
A model has been developed for the closer linking of clinical and
CARAT services in prisons to form an Integrated Drug Treatment
System (IDTS). 
The principal features of IDTS are integrated screening, triage
assessment, comprehensive substance misuse assessment and
care planning to provide access to a wide range of prescribing
and psychosocial treatment, incorporating early effective clinical
intervention and enhanced psychosocial support for the first 28
days of custody. Guidance on the psychological support in IDTS
will be available from NOMS.29 The clinical elements of IDTS are
described in detail in Department of Health guidance – Clinical
Management of Drug Dependence in the Adult Prison Setting –
scheduled for publication in 2006.22
3.4.3 Drug treatment programmes
These are available in over 100 prisons and provide a range of
programmes, including:
• Short duration programmes (Tier 3) available for those on
remand or short sentences, who are unable to engage in
longer programmes. These will be an important component of
the short custodial periods available under the Custody Plus
sentence when this is implemented in 2006. Short duration
programmes may also be used as a booster, prior to release,
for those who have previously completed another programme
(Tier 3)
• Cognitive-behaviour therapy programmes (Tier 3), e.g. 
P-ASRO (Prison – Addressing Substance-Related Offending),
for those serving longer sentences, designed to give the
thinking skills needed to help drug misusers to overcome drug
dependency and to adopt a more sustainable lifestyle
• The 12-Step programme (Tier 3 and Tier 4), based on the
Minnesota Model of addiction (e.g. as used by Alcoholics
Anonymous)
• Therapeutic communities (Tier 4), designed for those with the
most severe drug-misuse needs, delivered over eight months
to a year.
3.5 Primary care 
3.5.1 Primary care interventions across four tiers
Many clients’ initial or main contact with drug treatment is through
primary care. GPs and primary healthcare teams are valuable in
delivering a wide range of interventions and can provide
interventions covering all four tiers, where appropriate, provided
the GPs or practitioners are competent to do so. This may
involve:
Tier 1 interventions – screening drug-using clients and referring
them on to other service providers; provision of general medical
services (GMS). Under the terms of the GP contract, all GPs must
provide Tier 1 interventions.
Tier 2 interventions – triage assessments, harm reduction. All
practices can provide at least some Tier 2 interventions via the
primary healthcare team as a whole (e.g. simple harm
minimisation advice, brief interventions and immunisations).
Tier 3 interventions – prescribing for drug users within the context
of a care plan. Many GPs provide Tier 3 services under specific
contractual arrangements.
Tier 4 interventions – medical monitoring of residential
rehabilitation or detoxification services, provided by a few GPs
where there is local need.
3.5.2 Different contractual arrangements for shared
care and primary care based treatment
Changes in GP contracts since Models of Care (2002) have
implications for the commissioning and delivery of drug treatment
services. Changes introduced as a result of the new contracts
should ensure the stability, ongoing development and continued
expansion of drug treatment systems to meet the key targets of
doubling the number of people in treatment and increasing the
proportion appropriately retained or completing treatment.
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As well as providing the core general medical services to
substance misusers, a number of different contractual
arrangements may be utilised to commission appropriate primary
care-based drug treatments, including shared care, to meet local
needs. These include:
• Contracts for nationally enhanced services (NES) or locally
enhanced services (LES) under the new GP Contract (nGMS)
for GPs in shared care schemes with specialist support.
– Nationally enhanced services (NES) for drug misusers
have nationally negotiated specifications and payments,
including requirements for GPs to engage in limited clini-
cal governance activities and remuneration arrangements
based on treatment modalities, which may be used if
suitable 
– Locally enhanced services (LES) for drug misusers, which
allow wide flexibility in determining service specifications.
Many PCTs have negotiated LES contracts in preference
to NES contracts, in response to an emerging evidence
base on best practice, improved clinical governance and
remuneration packages suited to a local context.
• Personal medical services (PMS) contracts are another well-
established mechanism for arriving at locally negotiated
service level agreements. These can provide different levels of
care, from simple prescribing in shared care arrangements to
full packages of care delivered by whole teams from a primary
care base or from separate clinics. PMS arrangements have
been set up to deliver services to specific vulnerable patient
groups, such as homeless people, refugees and sex workers.
These services will be based in an established primary care
base or a separate setting with a strong primary care ethos,
and provide a range of services including drug treatment.
Either type of contract may allow for a GP practice to collaborate
in a shared care arrangement with drugs workers who are either
employed by specialist agencies, or for the more autonomous
practice to employ such staff directly.
For more information on drug treatment and the new GMS
(nGMS) contract, with NTA recommendations and consensus
reached at a provider summit held by the NTA in December 2003,
see the NTA website www.nta.nhs.uk.
Additionally, doctors with a primary care background may be
employed by voluntary or non-statutory agencies, criminal justice
agencies, or independent sector providers to provide a range of
levels of care, with individually negotiated service level
agreements.
3.5.3 Competences for doctors in primary care drug
treatment
Commissioners should ensure local treatment systems have a
complete spectrum of medical provisions to meet the range of
needs and the numbers of substance misusers entering
treatment. This requires a variety of skills and competences at
various levels, from simply providing general medical skills, to GPs
offering less complex drug treatments, to specialist addictions
skills and addiction psychiatry skills. This is a key message arising
from the consensus document produced by the Royal College of
General Practitioners and the Royal College of Psychiatrists –
Roles and Responsibilities of Doctors in the Provision Of
Treatment for Drug and Alcohol Misusers (2005)30 – as
summarised in an NTA briefing note on its website,
www.nta.nhs.uk. The consensus document specifies a hierarchy
of roles for GPs, with increasing competency levels:
• GPs providing core services. A doctor providing general
medical care only to substance misusers
• GPs providing enhanced services. A doctor providing basic
medical care plus care to substance misusers, in accordance
with locally agreed shared care guidelines
• GPs with special clinical interest (GPwSI) providing
enhanced services. GPwSIs have received specific higher
level training in the management of substance misusers in
primary care, usually the GP Certificate in Management of
Drug Use Part 2. GPwSIs delivering locally enhanced services
or nationally enhanced services are able to work more
autonomously and take responsibility for more complex cases
in substance misuse than other GPs
• Substance misuse specialist (primary care). A doctor with
a general practice background and an extensive postgraduate
training in substance misuse working as a specialist GP lead
or director employed by a PCT or mental health trust. These
doctors are able to take on most complex cases, and where
competences and accreditation allow, highly specialised
areas, such as management of severe and enduring mental
illness (in conjunction with specialist psychiatric support and
appropriate clinical governance) and prescribing of heroin for
treatment of addiction (under license). These doctors have
responsibility for the full range of clinical governance activities
and service development for substance misuse in their parent
NHS trust. They are expected to have extensive postgraduate
training in substance misuse, regular clinical supervision, CPD
and peer support.
3.5.4 Models of drug treatment in primary care
A number of actual models of primary care drug treatment have
evolved in the context of local resources and identification of
need. These models include various types of shared care services
in which GP services are supported by more specialist service
provision, and primary care-led drugs services, which may or may
not have shared care arrangements with a secondary care
provider.
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Shared care services 
Commissioners should ensure that every local area has shared
care arrangements in place. There are many different models of
shared care but the underpinning principles are:
• Patients in all local areas should have access, where clinically
appropriate (usually the more stable patients), to long-term
care – even after exit from drug treatment – and community-
based multidisciplinary support inherent in the primary care
setting
• There should be unobstructed transfer of patients between
the services sharing their care as their clinical needs change.
There are a wide range of models of shared care, which may
include the following variations:
• GPs or non-medical prescribers commissioned as providers
of drug treatment, and depending on arrangements and level
of competence, offering different levels of care from long-term
maintenance prescribing in shared care arrangements to more
specialised packages of care for complex needs
• Drug treatment delivered from a base in a primary care setting
by a multidisciplinary team, to patients registered with those
GPs or patients registered with other GPs in the locality
• Support for specialist provision from primary care, or more
usually secondary care-led services, which provide shared
care support and direct care for more severe and complex
cases
• Arrangements set up to deliver services to specific vulnerable
patient groups, such as homeless people, refugees and sex
workers. These services will be based in primary care and
provide a range of services including drug treatment and have
often been commissioned as personal medical services. They
are supported by specialist secondary care drug services,
which provide direct care, particularly for more severe or
complex cases.
Whatever models of shared care are commissioned locally, they
should be commissioned according to local needs, and in line
with medical competences30 and appropriate clinical governance
arrangements. These shared care arrangements should be
reviewed, refined and developed regularly.
Primary care-led services
Some areas may have a primary care-led service depending on
the local configuration of specialist services. In these services,
GPs act as clinical leads for community drug services, where
there is no formal secondary care or specialist addiction
psychiatry leadership available within the service or through
shared care arrangements.
Commissioners may support such arrangements because of the
advanced specialist competence of the particular GPs involved
(e.g. as described in Roles and Responsibilities of Doctors in the
Provision of Treatment for Drug and Alcohol Misusers).30
Sometimes the GP may act as a clinical lead in substance misuse
for their area in conjunction with specialist psychiatric support.
This may be in a service overseen by or in partnership with an
addiction psychiatry team.
Primary care-led services may sometimes be commissioned in
this role because it has not been possible to obtain suitable
shared care support in the area. However, this is not ideal and
suitable shared care services should be encouraged and
developed in every area.
It is important to ensure that the needs of the most severe and
complex patients are adequately addressed in any system. There
are clearly advantages for patients in having access to a range of
provision, from GPs with a range of competences and from
secondary care specialists across an integrated system of care.
3.6 Inpatient treatment and residential 
rehabilitation: The need for expansion
Inpatient substance misuse treatment and residential rehabilitation
(Tier 4) interventions have not expanded at the same rate as Tier
2 and Tier 3 drug treatment provision in the last few years. The
coverage of Tier 4 interventions in England is still inconsistent and
substance misuse inpatient treatment and residential rehabilitation
are sometimes only (incorrectly) used as a last resort for drug
misusers, when Tier 4 interventions should be available to clients
at different stages in their treatment journeys. Commissioning to
expand Tier 4 is crucial to improve clients’ journeys and to
maximise treatment exits and access to abstinence-based
aftercare. The development of inpatient treatment and residential
rehabilitation services is of increasing importance for a number of
reasons:
• There is high level of expressed need for residential provision
from service users and carers
• Specialist inpatient interventions – assessment, stabilisation
and assisted withdrawal/detoxification – are necessary to
provide the optimal local drug treatment system for clients
with complex drug, alcohol and other health needs; those in
crisis; those requiring medication stabilisation (e.g. on
injectable or high-dose opioids, or for effective detoxification)
• Inpatient detoxification followed by residential rehabilitation is
the most effective way for drug misusers to become drug-
free, if they are motivated and this is the agreed objective
(NTA, 2005)31
• There is evidence to show that detoxification in specialist
substance misuse facilities is more effective than in general
hospital or psychiatric wards, which are associated with low
success rates32
• It is recognised that service users must have social support
upon leaving rehabilitation units and secure adequate housing
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to maximise the benefits of treatment and to reduce risk of
relapse and fatal overdose.
The commissioning of all Tier 4 interventions requires
improvement. Some of the services (mainly residential
rehabilitation units) providing these interventions have national
catchment areas, and can be particularly vulnerable if they are
continually “spot purchased”. It is important to note that these
interventions can be purchased using pooled treatment budget
funding, community care funding, mainstream health funding, or
some combination of these. The commissioning of inpatient and
residential rehabilitation services should be undertaken within an
integrated care pathway approach that is embedded within local
strategic annual treatment planning process and joint
commissioning systems. These pathways should be
commissioned with clear routes into inpatient services, which lead
to residential rehabilitation (if required) followed by a substance
misuse support package, including housing if necessary.
From 2006, new regional or sub-regional commissioning
arrangements will be developed, which will require working across
strategic partnerships on a regional or sub-regional basis to
strategically plan and commission Tier 4 treatment.
Initial guidance for commissioning Tier 4 treatment33 was issued
in February 2006 (further guidance is planned for later in 2006).
This guidance emphasises the need to increase inpatient and
residential rehabilitation provision to create more planned exits
from drug treatment for those who want it, in line with the
Treatment Effectiveness strategy. It focuses on:
• The effectiveness of Tier 4 treatment
• The importance of commissioning integrated care pathways
for Tier 4 treatment
• Commissioning based on assessment of need for Tier 4
treatment
• Using a mixed economy to purchase or commission Tier 4
treatment. In particular, sole reliance on community care
funding for residential rehabilitation will not be enough, and
other funding arrangements should also be used
• A mixture of block and spot purchasing of residential
rehabilitation places
• A move towards contracting with preferred providers who
demonstrate quality
• Improved performance management arrangements (including
standard contracts and NDTMS compliance).
Future guidance is planned which will further emphasise strategic
regional and sub-regional commissioning of Tier 4 treatment.
3.7 Greater emphasis on aftercare
Models of Care: Update 2006 seeks to clarify and describe
aftercare as both drug related and non-drug related support (see
section 9.10 for more details). To aid effective and well co-
ordinated commissioning, drug-related aftercare provision (i.e.
support to specifically address a person’s drug dependency
issues) should be commissioned through inclusion in DAT
partnership annual treatment plans. Non-drug related aftercare
support (i.e. support that does not directly address drug
dependence) is provided by partner agencies and is not usually
directly commissioned through drug treatment plans.
Commissioners should ensure that necessary local partnership
arrangements are in place to enable adequate service provision
for clients leaving drug treatment.
Aftercare is increasing in importance as more drug users are
entering and going through treatment programmes. This raises
the need for both drug-related and non-drug related aftercare
support to be in place when they leave treatment, so that positive
changes they have achieved in drug use – criminal activity, health
and social functioning – are maintained. In strategic planning and
commissioning of aftercare services, it is important that
commissioners give consideration to the following areas, which
can also be key to client engagement and retention:
• Ensuring continuity of care for those leaving treatment,
finishing a community sentence or moving between the
community and custody
• Making clear links to housing provision through local authority
homelessness strategies
• Establishing access and links to local and mainstream
programmes for wraparound support (such as housing,
employment, training and education)
• Establishing links to other services (such as alcohol and
mental health services) as appropriate
• Developing relapse prevention support (outside existing
treatment provision), support for families, peer support for
drug users leaving treatment, and providing mentors.
It is particularly important that housing and support services are in
place, where required, for people leaving inpatient treatment and
residential rehabilitation. Agencies providing Tier 4 interventions
need to have good connections with social care and other
services that can provide, or can facilitate provision of, the
aftercare a client needs when they leave treatment. Guidance has
been issued by ODPM and the Home Office,34 which emphasises
that Supporting People funding should be considered in tandem
with other funding streams, such as the drug pooled treatment
budget and the DIP main grant, and in line with the drug action
team treatment plans, local homelessness strategy and
Supporting People strategy, to provide the basis for a locally
joined-up approach. The Home Office and ODPM have also
issued a briefing outlining further examples of joint working and
practice.35
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3.8 The four tiers reiterated
The following reiteration of the tiers describes:
• The drug interventions it is best practice to commission and
provide in each local area
• The range of settings these are normally provided in
• The competence or level of drug treatment skills and training
that is normally required.
Commissioners need to ensure that all tiers of interventions are
commissioned to form a local drug treatment system to meet
local population needs. Local systems should allow for some
flexibility in how interventions are provided, with the crucial factors
being the patterns of local need and whether a service provider is
competent to provide a particular drug treatment intervention.
3.9 Treatment effectiveness: Improving clients’ journeys 
3.9.1 Evidence for treatment effectiveness
Models of Care: Update 2006 has a greater focus on improving
clients’ treatment journeys through systems. Drug treatment is not
an event, but a process usually involving engagement with
different drug treatment services, perhaps over many years. Each
client’s drug treatment journey is different and depends on a
range of factors including health status, relationships, nature of
the drug problem and the quality of the drug treatment they
receive. However, drug treatment use is often episodic, with
service users dipping in and out of treatment over time. Evidence
from the US36 suggests that an average time in treatment for
someone with a heroin or crack dependence problem is five to
seven years, with some heroin users requiring indefinite
maintenance on substitute opioids. Evidence also tells us that
service users gain cumulative benefit from a series of treatment
episodes. However, the biggest improvements in client outcomes
are likely to be made in the first six years of treatment (DATOS).37
Evidence indicates that entry into treatment has an immediate
positive impact on drug use and crime, particularly for someone
prescribed substitute medication. However, this is not sustained if
the client is not retained in treatment. Optimised treatment usually
involves retaining clients in drug treatment for a minimum of three
months. This is the point at which treatment begins to accrue
generalised long-term benefit. Engaging the service user
sufficiently in a therapeutic relationship enables positive lifestyle
changes to occur. This approach requires a partnership between
the treatment provider and the client or service user, with both
working towards common explicit goals. This also requires a
concerted effort on behalf of the treatment provider to enable all
of the clients’ needs to be met, not just their drug treatment
needs. This may include addressing alcohol misuse, health needs
due to blood-borne virus infections such as hepatitis C, treatment
for underlying anxiety or depression, building social support
networks, and providing access to appropriate housing,
education or employment. All of these may be crucial to prevent
relapse back to illicit drug misuse.
While much of the focus of outcome research has been on
identifying key individual characteristics that predict better
treatment outcomes, such as higher levels of personal and social
capital and lower levels of problem severity, increasing attention is
being paid to service characteristics that can improve outcomes.
The National Drug Evidence Centre research (2004)23 for the NTA
showed that the best predictor of retention in community
treatments in the north-west of England was related to service
factors rather than client characteristics. Similarly, Meier (2005)38
has also reported that much of the variability in retention in
residential rehabilitation services derives from the service itself
rather than the service user. This is consistent with empirical
research conducted in the US, which shows that organisational
development work can lead to significantly enhanced treatment
outcomes across patient populations.37
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Definition Tier 1 interventions include provision of drug-related information and advice, screening and referral to specialised
drug treatment.
Interventions Commissioners need to ensure that a range of generic services provide, as a minimum, the following 
Tier 1 drug interventions:
• Drug treatment screening and assessment
• Referral to specialised drug treatment
• Drug advice and information 
• Partnership or “shared care” working with specialised drug treatment services, to provide specific drug
treatment interventions for drug misusers within the context of their generic services. Specific drug treatment
liaison schemes may need to be commissioned to fully realise partnership work.
Generic services should also provide their own services to drug misusers and some may be specifically designed
for drug misusers (e.g. housing projects for those leaving rehabilitation). Commissioners should ensure that drug
misusers are not marginalised from generic services by developing local strategic partnerships.
Settings Tier 1 interventions are provided in the context of general healthcare settings (e.g. liver units, antenatal wards,
Accident and Emergency and pharmacies), or social care, education or criminal justice settings (probation, courts,
prison reception) where the main focus is not drug treatment.
Competency Staff require competence to screen and identify drug misuse and refer into local specialised drug treatment
systems, in accordance with local protocols, to provide drug-related advice and information and to work in
partnership with specialist drug treatment services.
Commissioners may need to ensure competency-based training, information on local systems and drug liaison
workers to support partnership projects.
Of particular relevance are DANOS39 Standards (Drug and Alcohol National Occupational Standards): AA1
“Recognise indication of substance misuse and refer to specialists”; AB2 “Support individuals who are substance
misusers”; AB5 “Assess and act on risk of danger to substance misusers”, and AF1 “Carry out screening and
referral assessment”.
Tier 1 interventions: Drug-related information and advice, screening and referral by generic services
Tier 1 interventions
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Definition Tier 2 interventions include provision of drug-related information and advice, triage assessment, referral to
structured drug treatment, brief psychosocial interventions, harm reduction interventions (including needle
exchange) and aftercare.
Interventions Tier 2 interventions that should be commissioned in each local area include:
• Triage assessment and referral for structured drug treatment
• Drug interventions which attract and motivate drug misusers into local treatment systems, including
engagement with priority groups, such as pregnant women, offenders and stimulant users
• Interventions to reduce harm and risk due to BBVs and other infections for active drug users, including
dedicated needle exchanges and the support and co-ordination of pharmacy-based needle exchanges
• Interventions to minimise the risk of overdose and diversion of prescribed drugs 
• Brief psychosocial interventions for drug and alcohol misuse (including for stimulants and cannabis problems if
it does not require structured treatment) 
• Brief interventions for specific target groups including high-risk and other priority groups
• Drug-related support for clients seeking abstinence
• Drug-related aftercare support for those who have left care-planned structured treatment
• Liaison and support for generic providers of Tier 1 interventions
• Outreach services to engage clients into treatment and to re-engage people who have dropped out of
treatment
• A range of the above interventions for drug-misusing offenders.
Settings Tier 2 interventions may be delivered separately from Tier 3 but will often also be delivered in the same setting and
by the same staff as Tier 3 interventions.
Other typical settings to increase access are through outreach (general detached or street work, peripatetic work
in generic services or domiciliary (home) visits) and in primary care settings.
Pharmacy settings are important due to their unique role in pharmacy based needle exchange schemes and their
role in supervised consumption of prescribed drugs.
Criminal justice settings – including initial contact and assessment by CJIT workers in police custody suites,
magistrates courts and crown courts – working closely with probation as well as CARATs and prison healthcare
provision within the prisons estate.
Drug treatment interventions for offenders may be delivered in the community by CJIT workers and in prison by
CARATs and some drug treatment programmes.
Competency Tier 2 interventions require competent drug and alcohol specialist workers who should have basic competences in
line with DANOS.39
Competency also depends on what cluster of services are provided. Normally, frontline staff would have
competence in motivational techniques and drug and alcohol brief interventions. Those advising on injecting
techniques should be DANOS competent with, as best practice, some members of the team having nursing or
medical qualifications.
Those providing extended pharmacy-based services for drug misusers, including interactive needle exchange and
supervised consumption services, would normally have drug specific competence, may have specific contractual
arrangements with drug treatment commissioners and work in partnership with other community-based drug
services. 
Tier 2 interventions: Open access, non-care-planned drug-specific interventions
Tier 2 interventions
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Definition Tier 3 interventions include provision of community-based specialised drug assessment and co-ordinated care-
planned treatment and drug specialist liaison.
Interventions Tier 3 interventions that should be commissioned in each local area include:
• Comprehensive drug misuse assessment 
• Care planning, co-ordination and review for all in structured treatment, often with regular keyworking sessions
as standard practice
• Community care assessment and case management for drug misusers
• Harm reduction activities as integral to care-planned treatment
• A range of prescribing interventions, in the context of a package of care and in line with Drug Misuse and
Dependence – Guidelines on Clinical Management,21 known as “the clinical guidelines”. This will be updated
alongside the relevant forthcoming National Institute for Clinical Excellence (NICE) guidelines and technology
appraisals, and in line with other evidence-based clinical standards with specific interventions, including:
prescribing for stabilisation and oral opioid maintenance prescribing; community based detoxification;
injectable maintenance prescribing, and a range of prescribing interventions to prevent relapse and ameliorate
drug and alcohol-related conditions
• A range of structured evidence-based psychosocial interventions to assist individuals to make changes in drug
and alcohol using behaviour 
• Structured day programmes and care-planned day care (e.g. interventions targeting specific groups)
• Liaison services for acute medical and psychiatric health services (e.g. pregnancy, mental health and hepatitis
services)
• Liaison services for social care services (e.g. social services (child protection and community care teams),
housing, homelessness)
• A range of the above interventions for drug-misusing offenders. 
Settings Tier 3 interventions are normally delivered in specialised drug treatment services with their own premises in the
community or on hospital sites. Other delivery may be by outreach (peripatetic work in generic services or other
agencies or domiciliary or home visits). Tier 3 interventions may be delivered alongside Tier 2 interventions.
Some of the Tier 3 work is based in primary care settings (shared care schemes and GP-led prescribing services),
as well as pharmacies, but drug specialist-led services are required within the local systems for the provision of
care for severe or complex needs and to support primary care.
Drug treatment interventions for offenders may be delivered in prison settings by CARATs and some drug
treatment programmes 
Community criminal justice programmes, such as DRRs, are delivered in contracted community drug treatment
services (statutory or voluntary) or in-house by probation staff on probation premises.
Competency Tier 3 services require competent drug and alcohol specialised practitioners who should have competences in line
with DANOS.39 The range of competences required will depend upon job specifications and remits.
Medical staff (usually addiction psychiatrists and GPs) will require different levels of competences depending on
their roles in drug treatment systems and the needs of the client, with each local system requiring a range of
doctor competences (from specialist to generalist) in line with joint guidance from the Royal College of General
Practitioners and the Royal College of Psychiatrists.30
Tier 3 interventions: Structured, care-planned drug treatment
Tier 3 interventions
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Definition Tier 4 interventions include provision of residential specialised drug treatment, which is care planned and care co-
ordinated to ensure continuity of care and aftercare. 
Interventions Tier 4 interventions that should be commissioned to meet local area needs include: 
• Inpatient specialist drug and alcohol assessment, stabilisation, and detoxification/assisted withdrawal services
• A range of drug and alcohol residential rehabilitation units to suit the needs of different service users
• A range of drug halfway houses or supportive accommodation for drug misusers
• Residential drug and alcohol crisis intervention units (in larger urban areas)
• Inpatient detoxification/assisted withdrawal provision, directly attached to residential rehabilitation units for
suitable individuals
• Provision for special groups for which a need is identified (e.g. for drug-using pregnant women, drug users
with liver problems, drugs users with severe and enduring mental illness). These interventions may require joint
initiatives between specialised drug services and other specialist inpatient units
• A range of the above interventions for drug-misusing offenders.
Settings Ideal settings to provide inpatient drug detoxification and stabilisation are specialised dedicated inpatient or
residential substance misuse units or wards.
Inpatient provision in the context of general psychiatric wards may only be suitable for some patients with co-
morbid severe and enduring mental illness, but many such patients will benefit from a dedicated addiction
specialist inpatient unit.
Those with complex drug and other needs requiring inpatient interventions may require hospitalisation for their
other needs – for example pregnancy, liver problems and HIV-related problems – and this may be best provided
for in the context of those hospital services (with specialised liaison support). 
Continuity of care is essential for preserving gains achieved in residential treatments. Therefore, there is a compelling
argument for providing, for suitable patients, inpatient detoxification beds attached to residential rehabilitation units
(provided there are adequate medical supports). Other patients need inpatient detoxification first in an addiction
specialist inpatient unit (e.g. because of severity and complexity), but this still requires significant strengthening of
the links with residential rehabilitation provision, to ensure the seamless transition of clients between the two.
Service users requiring residential rehabilitation or halfway houses may wish to be located away from their area of
residence and drug misusing networks.
Within prisons, specialist detoxification units, therapeutic communities (drug specific) and some (residential) 12-
Step programmes are Tier 4 interventions.
Competency Inpatient or residential interventions providing detoxification and pharmacological stabilisation would normally
require medical staff with specialised substance misuse competency (rather than be provided by generalist GPs).
The level of specialised medical staff competence required will depend on the types of services provided and the
severity of the problems of the clients. Addiction specialist competences will be needed for inpatient units for
severe and complex problems, but suitably competent GPs can provide support to some units for patients with
less complex needs.
Staff in residential rehabilitation units that are registered care homes will need to meet relevant social care National
Occupational Standards and relevant standards currently inspected and monitored by the Commission for Social
Care Inspection. Hospital-based services will also be required to meet practitioner standards for independent or
NHS hospitals currently inspected and monitored by the Healthcare Commission.
Non-registered residential rehabilitation services should meet other appropriate standards, where applicable, e.g.
Supporting People arrangements, EATA accreditation.
All staff working in all residential settings are advised to demonstrate competence against DANOS39 at both
manager and practitioner levels.
Tier 4 interventions: Drug specialist inpatient treatment and residential rehabilitation
Tier 4 interventions
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3.9.2 Component parts of the treatment journey
In addition to implementing the framework advocated in Models
of Care 2002, the NTA is committed to pushing for an
improvement in drug treatment effectiveness. The Treatment
Effectiveness strategy, with a focus on improving clients’ journeys
through drug treatment, is integrated in Models of Care: Update
2006. The treatment journey is conceptualised into four
overlapping components, each with key objectives. These
components are illustrated in Figure 1 and comprise: 
• Treatment engagement
• Treatment delivery (including maintenance)
• Community integration (which underpins both delivery and
treatment maintenance or completion) 
• Treatment completion (for all those who chose to be drug-free
and who can benefit).
Although it will be useful to see these phases of the treatment
journey as conceptually separate, there is room for considerable
overlap. It is important to note that the phases do not mean that
treatment is a linear journey, with service users progressing
through the three main phases of engagement, delivery and
completion. Instead, these are the main elements of a treatment
journey which may occur in a variety of combinations during a
client’s time in treatment. Considering these phases can be
particularly helpful in informing the focus of care plans at different
stages and in maintaining a focus on the treatment journey.
Treatment engagement
The treatment system needs to be able to engage people rapidly
and retain them once they have entered treatment. Two issues
important to improving treatment engagement are timely access
to treatment and a focus on supporting retention for at least three
months in structured treatment for adults with dependent drug
misuse. Each drug treatment system will be assessed on its ability
to engage service users on these two issues, through
performance management on national waiting times and retention
targets by the NTA, as outlined in the Government’s treatment
effectiveness strategy.
During the engagement phase of treatment, service users will
need to be assessed to ensure treatment can be tailored to their
needs and at this stage they may benefit from motivational work
focused on maximising engagement. Particular consideration may
need to be given to preventing disengagement of certain drug
users (e.g. those from some Black and minority ethnic groups,
younger drug users and clients with mental health and substance
misuse problems). The engagement of service users may be
enhanced by a specific process of induction into treatment, so it
is made clear and comprehensible for individuals what are the
roles and responsibilities of the service provider and what are the
expectations on service users themselves.
Following assessment, care plans will be agreed with the clients
and structured treatment will begin. There also needs to be more
explicit commissioning of interventions that engage service users
and build “therapeutic alliances”, which are crucial to treatment
retention and positive changes in treatment.
A range of interventions to support engagement could be
explicitly commissioned, including brief interventions, services for
the children of drug users, advocacy and support arrangements
and interventions to contact, engage and follow up people (e.g.
outreach for rough sleepers, motivational interventions).
Drug treatment delivery
Drug treatment providers need to deliver effective and evidence-
based drug treatment interventions, following completion of a care
plan that has been agreed with the client. Drug treatment
practitioners should work to build an effective therapeutic alliance
with service users, encouraging full participation by them in
delivering their own care plans. Good-quality drug treatment
should be associated with improvement across a range of
domains, including an individual’s substance use, health, social
functioning and in reduced public health and offending risks
posed to others.
In delivery of drug treatment, a greater emphasis is required on
improving service users’ physical and mental health, importantly
for those with hepatitis C infection and for those misusing alcohol.
Increases in the use of cocaine and crack cocaine by service
users may have a negative impact on client outcomes, unless this
is addressed, particularly with injecting drug users.
The children, carers or significant others of service users should
also be considered during care-planned treatment. The needs of
the children of drug-misusing parents also require greater
attention (ACMD, 2004).40
During this phase, clients should begin to receive other
interventions to meet their wider needs. These interventions could
include improving housing status, getting other healthcare needs
met by other health specialists (e.g. liver disease and dentistry),
help with children and family issues, and provision of assistance
to enable service user back to work or education. These non-
drug treatment interventions should be set out in the client’s care
plan and links made with appropriate services to ensure the client
receives them. This includes the initiation of elements of
community integration.
To ensure that the delivery of drug treatment meets the client’s
needs in a timely way, local treatment systems must ensure
continuity of care between the criminal justice system and drug
treatment. This is particularly relevant for clients entering and
leaving prison.
Clients who are on long-term maintenance (ideally in shared care)
should be considered to be continuing in the delivery phase of
treatment.
24
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Improving community integration 
Whether service users are in treatment (e.g. maintained on
substitute opiate medication) or leaving treatment they should
have access for social support (e.g. housing support, educational
support, employment opportunities) to maximise positive gains
they have made in treatment.
Service users who are stable but who wish to be maintained on
substitute opioid medication should have opportunities to receive
social support, education and employment where appropriate.
For stable individuals who do not need to continue in specialised
drug treatment services, there should be clear pathways into
maintenance and monitoring in primary care settings with ongoing
community integration interventions and support. However, it is
vital that such service users have explicit accessible pathways
back into specialised structured drug treatment services if needed
(e.g. in case of relapse). 
DAT partnerships should consider linking their drug treatment
targets to wider mainstream targets, that relate to housing,
education and employment for drug users (e.g. Office of the
Deputy Prime Minister for Supporting People, Department of
Work and Pensions for Jobcentre Plus and Progress2Work).
Improving treatment completion
Few service users who enter drug treatment intend to be in
specialist drug treatment indefinitely. For those who wish to be
drug-free, commissioners and providers need to create better
pathways and exits from specialist drug treatment.
These pathways should include drug-related and non-drug-
related support. Drug treatment providers and commissioners are
responsible for the drug-related support, and should form the
necessary local strategic links to enable clients to access non-
drug-related support, including improved social support, housing,
education and employment opportunities to maximise treatment
gains.
This approach will require treatment systems to be configured
both to create effective exit routes out of specialised drug
treatment, including efficient access to Tier 4 provision for those
who wish to be drug-free, and to be well integrated with primary
care and other systems of support and care for those in
maintenance treatment.
Drug-related aftercare support, such as support groups or
individualised sessions or alternatively from mutual aid groups run
by Narcotics Anonymous or non-12-Step equivalent groups, has
been demonstrated to sustain abstinence.
Improving community integration and treatment completion may
require some drug treatment system or service redesign,
including: 
• As well as planning for numbers in treatment and numbers of
clients retained in treatment, commissioners should plan for
numbers of planned client exits from treatment
• Investing in quality drug treatment delivery to maximise gains
and service users’ improvement in treatment (whether
achieving stability on maintenance treatment or achieving
effective abstinence)
• Enhancing routes to treatment completion or, for stable
patients who no longer need specialist care, better routes to
community maintenance in primary care settings
• Commissioning a range of aftercare provision for service users
to follow structured treatment, as a development of Tier 2
interventions, and ensuring a range of other support
mechanisms for ex-service users (e.g. drug-free support such
as Narcotics Anonymous or equivalents)
• Investing in strategic partnerships with housing, education and
employment, together with bespoke initiatives for drug
misusers aimed at reintegration.
25
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Figure 1: The client’s journey
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4 Substance misuse assessment
Substance misuse assessment is a process to establish the
nature and extent of drug and alcohol misuse, what level of need
an individual may have and what interventions are required.
Assessment varies in its depth and level of detail, depending on
the purpose and anticipated outcome of the assessment process.
Models of Care 2002 identified three levels of assessment:
screening, triage and comprehensive assessment, and provides a
detailed description of each level of assessment. The majority of
respondents to the consultations found the different levels in
Models of Care 2002 to be meaningful and useful. These are
reiterated here.
4.1 Screening assessment
Screening assessment is a brief process that aims to establish if
an individual has a drug and alcohol problem, related or co-
existent problems and whether there is any immediate risk for the
client. The assessment should identify those who require referral
to drug treatment services and the urgency of the referral.
Screening assessment may include an element of brief
opportunistic intervention aimed at engaging or preparing the
client for treatment. Screening assessment is likely to be carried
out in generic settings.
4.2 Triage assessment
Triage assessment usually takes place when a drug misuser first
contacts specialist drug treatment services. The aim of triage
assessment is to determine the seriousness and urgency of a
client’s problems and the most appropriate type of treatment for
the client. It involves a fuller assessment of the individual’s drug
and alcohol problems than is conducted at screening, as well as
assessment of a client’s motivation to engage in treatment,
current risk factors and the urgency of need to access treatment.
As a result of a triage assessment, a client might be offered
services within the assessing agency or onward referral to another
service. A further outcome of triage assessment is that, where
appropriate, work is undertaken to further engage and prepare
the client for treatment.
4.2.1 Assessment in the Drug Interventions Programme
Assessments of clients seen by CJIT workers in the community
and CARAT teams in prison are to be carried out within the
Models of Care framework.
A summary of the information from the assessment is collected
on the Drug Interventions Record (DIR). An effective DIR-based
assessment addresses the range of the client’s presenting needs
and covers health and social issues as well as drug use.
In the context of the DIR, the assessment is the key step towards
the development of an initial care plan and is also the first
important stage in gathering together, in a consistent way, the
information that will facilitate effective continuity of care for drug
users in the community and between community and prison.
Criminal justice integrated teams (CJITs) should all be able to
undertake assessments up to triage level and should have
resources available to the team to carry out more complex and
comprehensive assessments. It is important that practitioners only
carry out assessments according to their qualifications or
competence, and use the expertise of colleagues when
necessary.
4.3 Initial care plan
Following triage-level assessment, it may be good practice to
produce an initial care plan for clients. For clients taken onto the
CJIT caseload this will be essential, but it may also be useful in
other treatment services, particularly for clients who are identified
as at high risk, who have complex drug-related problems or are
likely to be hard to engage. Within prisons, initial care plans may
be appropriate for prisoners in the very early days of custody, or
those who are due to be released shortly after the triage is
undertaken.
The initial care plan is to facilitate a focus on a client’s
engagement in the treatment system, to ensure their immediate
needs are met, to build a therapeutic alliance and to ensure
appropriate support if they are waiting to undergo comprehensive
assessment. Not all clients will be required to undergo a
comprehensive assessment, and some may remain on their initial
care plan and be reviewed until they are discharged from
treatment.
The initial care plan is particularly relevant to CJIT/CARAT clients,
all of whom will receive an initial care plan after triage-level
assessment if taken onto the caseload. The initial care plan is set
at Tier 2 interventions level. If an initial care plan identifies the need
only for Tier 2 interventions, this will need to be reviewed with the
client at regular intervals. If the presenting needs increase, the
client may have to be referred for a comprehensive assessment.
Where a prisoner is in custody for a short period of time – up to
28 days – and there is insufficient time to progress to a
comprehensive assessment and care plan, an initial care plan
may be drawn up to ensure their immediate and throughcare
needs are met.
4.4 Comprehensive assessment
Comprehensive assessment is targeted at drug misusers with
more complex needs and those who will require structured drug
treatment interventions. The assessment aims to determine the
exact nature of the client’s drug and alcohol problems, and co-
existing problems in the other domains of health (mental and
physical), social functioning and offending. A full risk assessment
26
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should also be conducted. Comprehensive assessment may be
conducted by more than one member of a multidisciplinary team,
because different competences may be necessary to assess
different areas of client need (e.g. a doctor needs to assess
clients for prescribing interventions involving controlled drugs – a
supplementary prescriber may also be involved; or a psychologist
may need to carry out psychometric assessment).
Comprehensive assessment can be seen as an ongoing process
rather than a single event. Comprehensive assessment will be
carried out when a client may:
• Require structured and/or intensive intervention
• Have significant psychiatric and/or physical co-morbidity
• Have significant level of risk of harm to self or others
• Be in contact with multiple service providers
• Have a history of disengagement from drug treatment services
• Be pregnant or have children “at risk”.
Comprehensive assessment provides information that will
contribute to the development of a care plan for a client.
4.5 Risk assessment
It is best practice to carry out risk assessment as part of
screening, triage and comprehensive assessment. Risk
assessment aims to identify whether the individual has, or has
had at some point in the past, certain experiences or displayed
certain behaviours that might lead to harm to self or others. The
main areas of risk requiring assessment are:
• Risk of suicide or self-harm 
• Risks associated with substance use (such as overdose) 
• Risk of harm to others (including harm to treatment staff, harm
to children and domestic violence)
• Risk of harm from others (including domestic violence)
• Risk of self-neglect.
If risks are identified, risk management plans need to be
developed and actioned to mitigate immediate risk. If a service
has concerns about the needs and safety of children of drug
misusers, local protocols should be followed, for example if there
are concerns about risk of significant harms, social services would
normally be involved in further assessment of risk. As with
comprehensive assessment, risk assessment is an ongoing
process and requires integration into care planning. Issues of risk
highlight the need for appropriate information sharing across
services and therefore the need for cross-agency policies and
plans, and for clarity with a client around the limits of
confidentiality.
4.6 Competences required to conduct assessments
The Drug and Alcohol National Occupational Standards
(DANOS)39 outline the basic competences for professionals to
undertake different levels of drug and alcohol assessment.
Comprehensive assessment is intended to be a multidisciplinary
process to ensure a holistic approach to client need. Where a
medical intervention is required, such as substitute prescribing or
a psychiatric evaluation, the assessment must be undertaken by
an appropriately trained doctor.
For more information on assessment, see the Care Planning
Practice Guide (NTA 2006).5
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5 Care planning
This section should be read alongside the Care Planning Practice
Guide,5 which contains more detailed information and guidance
on care planning.
5.1 The need for good-quality care planning 
and co-ordination of care
In Models of Care: Update 2006 there is a stronger focus on care
planning as central to drug treatment and a defining characteristic
of structured treatment. The Audit Commission report Drug
Misuse 2004 outlines the good progress that has been made
since 2002 to meet the recommendations of the 2002 report.
However, one of the areas that Drug Misuse 2004 highlights as
needing improvement is consistency in the quality of care
planning. The report concludes that care planning is frequently ad
hoc and should be a routine activity monitored by local drug
partnerships, in order to deliver the vision of integrated care
envisaged in current national guidance. It also recommends that
there should be performance indicators that focus on effective
care planning and aftercare outcomes.
The NTA has identified care planning as a key tenet in its
Treatment Effectiveness strategy, recognising that the combination
of good care planning, good co-ordination of care and frequent
reviews of care plans with service users, is the vehicle to deliver
improvements to individuals’ health and social functioning and
reduce the public health and crime risk they pose to others. The
NTA’s Business Plan 2005/0625 sets an objective that, by 2008,
all individuals in treatment have an identifiable written care plan,
which tracks their progress and is regularly reviewed with them.
5.2 Care planning in Models of Care: Update 2006 
This section sets out key principles for care planning and co-
ordination of care, and a summary of the process as it relates to a
client’s treatment journey. Further details on the NTA’s
recommendations for care planning are contained in the NTA
Care Planning Practice Guide. Consultation confirmed that people
in the drugs field wanted to see more emphasis on clients
achieving treatment goals through the delivery of a care plan and
the client treatment journey. Therefore, although the key principles
of care planning and the co-ordination of care set out in Models
of Care 2002 remain the same, there are some differences in
focus, which are consistent with the overall greater focus on the
client’s treatment journey. These are:
• The care planning process as the essential component of the
client treatment journey
• The importance of all clients receiving keyworking as a crucial
element of care-planned treatment
• A greater focus on clients’ participation in the care planning
process, where they are involved in producing and agreeing
their care plans. This is consistent with the consultation
response where an overwhelming majority of respondents
wanted to see more service user involvement in care planning
and review
• Ensuring the care plan actively covers meeting client needs in
the four key domains of – substance misuse, health (physical
and psychological), social functioning (including employment
and education), and offending behaviour. This will require
providers to work together to meet these multiple needs and
greater co-ordination of elements of the care plan
• The focus in care plans and keyworking on the main elements
in the treatment journey: engagement, delivery, and
completion or maintenance.
5.2.1 Care co-ordination
The previous levels of “standard” and “enhanced” care co-
ordination are no longer referred to in Models of Care: Update
2006. It is clear that clients have a range of needs, from simple to
highly complex, and this must be reflected in the care plan and
the intensity of care co-ordination. It is expected that the
keyworker would co-ordinate care in most cases. External care
co-ordination may be required where a client has multiple needs
or is under statutory obligations via the criminal justice system,
Care Programme Approach (CPA) etc. This enables services to
reflect on case mix in a more flexible way taking into account the
staff competences, client characteristics and client needs, as well
as the systems of multidisciplinary working that are in place.
5.3 Care planning
5.3.1 The care planning process 
Care planning is a process for setting goals based on the needs
identified by an assessment and planning interventions to meet
those goals with the client. Care planning is a core requirement of
structured drug treatment.
5.3.2 The care plan 
A care plan is an agreement on a plan of action between the
client and service provider. It should be a paper document which
is available to the client and kept on the client’s file. Care plans
should document and enable routine review of client needs,
subsequent goals and progress across four key domains: 
• Drug and alcohol misuse 
• Health (physical and psychological)
• Offending
• Social functioning (including housing, employment and
relationships).
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A care plan should be brief and readily understood by all parties
involved and should be a shared exercise between the client and
service.
The care plan should explicitly identify the roles of specific
individuals and services, and the client, in the delivery of the care
plan. Care plans should be reviewed both routinely and
opportunistically when a change in a client’s circumstances
makes it necessary.
For more details on care planning, see the Care Planning Practice
Guide.
Some clients, particularly those in contact with CJITs or CARAT
services, may have an initial care plan which has been drawn up
to address any immediate needs the client may have, or to ensure
their engagement in treatment. The initial care plan is specific and
targeted and may not address all four key domains above, but it
should still be an agreed plan between the client and the worker
from the CJIT, CARAT or treatment provider, and recorded and be
made available to the client. It should also be easily understood
and reviewed regularly.
5.3.3 Care planning and the treatment journey
This section describes the client treatment journey represented in
Figure 2 overleaf.
Clients may make contact and enter the treatment system
through a wide range of service providers, which may be
providing interventions across the tiers. These services should
provide screening and brief initial risk assessment to identify drug
and alcohol problems. problems in line with that described in
Models of Care: Update 2006 (and previously in Models of Care
2002). Up-to-date posters and leaflets should be available in
these services, concerning drug and alcohol issues. These will
include health promotion messages, harm reduction strategies
(including for example overdose prevention) and information on
where to get help. If necessary, referral to a more specialist
service should occur. Ideally, this should occur in line with a
written protocol or policy including referral criteria agreed with the
local DAT.
Some services, such as A&E departments and maternity services,
are particularly likely to have contact with drug users who have
not been in touch with specialist provision. NHS trusts providing
these services should ensure that they have policies in place to
ensure that they can make available to patients up-to-date advice
and information relating to drug misuse and specifically:
• The potential physical and psychological complications of
drug and alcohol misuse
• How to reduce safely the harms associated with drug use,
particularly overdose and blood-borne viruses
• How to reduce safely and stop the misuse of various illicit
drugs and alcohol
• How and where to access help for problems associated with
drug and alcohol misuse.
Once the drug problem has been identified (and if necessary,
referral has taken place) the client will receive a triage assessment
and brief initial risk assessment to identify the nature and extent of
their drug use, the seriousness and urgency of their problems and
the most appropriate type of treatment.
The issue of engaging and retaining a client in the early phases of
treatment may be addressed after either (or both) screening and
triage assessment. The need for a focus on continuing
engagement may continue beyond the comprehensive
assessment. Where interventions are required to engage the client
these may include:
• Psychosocial interventions (e.g. contingency management,
motivational interventions)
• Advice and information
• Harm reduction interventions
• Rapid access to prescribing
• Other interventions focused on engagement
• Interventions to help the client prepare for change
• Interventions to address specific needs that may impact on a
client remaining in treatment
• Access to pharmaceutical services or supervised
consumption of treatment medications and needle exchange.
In some situations, following the triage assessment, an initial care
plan may be drawn up by the keyworker to enable the client’s
engagement and to help retain them in the treatment system. The
initial care plan will ensure immediate needs are met and support
structures are in place, until they receive a comprehensive
assessment, where appropriate. This will apply to CARATs when
release is imminent and there is insufficient time to progress to a
comprehensive assessment and full care plan while in custody.
Clients in some service settings may not, at first, be considered to
require Tier 3 or Tier 4 interventions or to require a comprehensive
assessment (e.g. some CJIT or CARAT clients) and may not have
complex needs. In these cases, the clients will receive
interventions to address their identified needs. However, on review
of the initial care plan, a client may present with more complex
needs and therefore be considered to need a comprehensive
assessment, which should be arranged with the treatment
provider. Alternatively, the client may be discharged following
regular reviews of the initial care plan.
The comprehensive assessment will build on the engagement
work commenced in any initial care plan.
The comprehensive care plan will identify a range of interventions
to meet client needs in the four key domains. Regular keyworking
should either deliver or co-ordinate provision of the treatment
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interventions outlined in the care plan. Once the interventions
have started, treatment moves into the “delivery phase”, which
includes regular review of the care plan.
The final stage in the treatment journey is the “treatment
maintenance or treatment completion” phase. Clients should be
assisted to leave structured drug treatment when appropriate and
to maintain the changes they have achieved. This may involve
helping the client access a range of non-care-planned
community-based services, such as mutual aid groups, housing
support, employment, and training and education opportunities (if
they are not already receiving them). 
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Figure 2: Standard client treatment journey – with initial care plan option included
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It may also be appropriate for a proportion of opiate-using clients
to remain on maintenance prescribing regimes in the community,
i.e. remain in the treatment maintenance phase of structured
treatment. These clients will continue to have a keyworker and a
care plan which covers their needs across the four domains.
Clients who are being discharged from treatment should have an
aftercare plan covering both drug-related and non-drug-related
support, which is implemented through ensuring all the necessary
links are in place for the client to receive all the aftercare they
require.
For more detailed information on this process and how it works,
see the Care Planning Practice Guide.
5.3.4 Keyworking and the care planning process
The keyworker is the dedicated and named practitioner who is
responsible for ensuring the client’s care plan is delivered and
reviewed. This would normally be the practitioner in most regular
contact with the client. However, given the range of settings in
which structured treatment is provided, the keyworker may be a
drugs worker, nurse, doctor, or other health or criminal justice
professional.
Keyworking is a process undertaken by the keyworker to ensure
the delivery and ongoing review of the care plan. This would
normally involve regular meetings between the keyworker and the
client where progress against the care plan would be discussed
and goals revised as appropriate. The keyworker would normally
be a member of the multidisciplinary team responsible for
delivering most of the client’s care. Keyworking and care planning
are key elements of case management currently delivered by
CJITs and CARATs. These elements will also be aligned with
NOMS’ offender management arrangements where appropriate.
As good practice, keywork involves building a therapeutic
relationship with the client. This may involve drawing up an initial
care plan following triage to address immediate needs, followed
by developing and implanting a comprehensive care plan.
As a minimum, the following should be delivered during keywork
sessions:
• Developing and agreeing the care plan with the client,
implementation of the care plan and checking progress
against milestones in the care plan
• Information and advice on drug and alcohol misuse
• Harm reduction work and motivational interventions
• Other psychosocial and medical interventions may also be
delivered during keywork sessions, depending on the
competency of the keyworker.
In primary care, the keyworker may be the GP but more
commonly would be a drugs worker supporting the GP in a
shared care arrangement. In this setting, the keyworker will still
work within a care planning framework that adheres to the
principles described above. Therefore, the care plan will describe
how the specific roles and responsibilities of the GP, the shared
care worker and any others involved will be shared in delivering
co-ordinated care. Shared responsibilities will include monitoring
of compliance and continuity of care. The GP is likely to lead on
prescribing interventions, changes and additions to medication,
and the shared care worker is likely to lead on monitoring
progress against treatment goals, developing a holistic treatment
plan and in ensuring multidisciplinary discussion when
appropriate. For GPs working at a more specialist level (e.g. GP
with special interest) the roles may be different but in all cases this
will be clear in the care plan.
A keyworker role will be undertaken by a worker in the criminal
justice integrated team (CJIT), for those clients taken onto the
caseload following a triage assessment e.g. in a custody suite or
court. The worker will take the responsibility for agreeing the initial
care plan with the client, providing the motivational engagement,
referring the client to other specialist treatment interventions,
where appropriate, and co-ordinating links with other services
(e.g. housing and employment). If a client is successfully referred
to another specialist treatment service, that provider will usually
take on the keyworking responsibilities. However, the CJIT
keyworker may retain a role and be ready to re-engage the client
if they drop out of treatment, in negotiation with the treatment
provider.
Providers of wraparound support alongside CJITs may contribute
to aftercare planning and handover of keywork arrangements as
appropriate This should be reflected in the care plan.
CARATs will take on the role of the keyworker while the client is in
custody, to ensure continuity of care between both the
community and prison and during transfers between prisons.
Clients who are assessed as needing ongoing access to drug
treatment services in the community will be referred to the single
point of contact in the relevant CJIT, as long as the individual has
given their consent for information to be passed to the CJIT.
The CJIT will consider whether the individual is to be taken onto
the caseload of the CJIT. In those cases where it is appropriate
for the individual, this decision is based on the drug-related needs
of the individual and the capacity of the CJIT. The CJIT will
provide or broker access to treatment and wraparound services
as appropriate.
5.3.5 The three phases of keyworking
The treatment journey has three main phases. The keyworker has
a crucial role in ensuring the care plan adequately reflects the
important stages in care. This may be through delivering these
elements of care directly or by ensuring the care delivered by
others is adequately co-ordinated and reflects these elements.
We recognise that in many services the term keyworker is used to
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mean both the co-ordinator of the care plan and the main
deliverer of care.
Key elements the keyworker needs to address in developing the
care plan at each stage: 
Treatment engagement phase. Actions taken should include
interventions to engage the individual, building a therapeutic
relationship, ensuring risks of leaving treatment early are identified
and addressed, drawing up an initial care plan following triage-
level assessment to meet immediate needs (if this is required) and
developing and agreeing the care plan following comprehensive
assessment and initial implementation of the care plan.
Treatment delivery phase. The therapeutic relationship with the
client continues to be developed by the keyworker and others,
with the aim of active changes in drug use and lifestyle
improvement. The care plan is regularly reviewed and revised in
line with any changing needs, and liaison and collaboration with
other providers of care takes place, and risk of disengagement
continues to be addressed.
Long-term treatment or treatment completion. The keyworker
should ensure the care plan enables the client to remain in long-
term treatment when appropriate. This part of the care plan would
usually involve clients who are stable on maintenance on
substitute medication moving into shared care arrangements and
being maintained in primary care. The keyworker should also
address action to support clients who want to be drug-free, leave
treatment and maintain changes they have made while in
treatment. Alternatively, they may have to arrange the transfer of a
client to another service provider to continue treatment.
5.3.6 Care planning and co-ordination of care in the
criminal justice system 
Continuity of care is vital to the treatment and support given to
problematic drug-using offenders as they move between different
criminal justice and treatment agencies. Improving continuity of
care for clients is reliant upon seamless case management
through the effective provision and communication of timely,
targeted and correct information.
Ensuring that a drug-misusing offender is supported throughout
their contact with the criminal justice system, or treatment, is
essential to maximising their chances of remaining engaged in
treatment. Various individuals and agencies may be involved in the
case management of an offender at different stages and it is
essential that the process is as continuous and uninterrupted as
possible for the individual concerned. The Drug Interventions
Record (DIR) establishes a common recording tool for use by
CJITs in the community, and counselling, assessment, referral,
advice and throughcare services (CARATs) in prisons. It contains a
minimum set of data for monitoring and provides information on
continuity of care, including continuity between the prison and the
community treatment. In prison, the DIR is used as a means to
record the substance misuse triage assessment.
It is important that at each stage of the care plan the keyworker
considers whether other professionals are also involved with the
individual and whether (within the legal framework) they should be
liaising and exchanging information with other individuals or
agencies. Offenders on statutory supervision should have links
with the appropriate offender management arrangements.
For more on the roles of CJITS and CARAT teams in care
planning, see section 5.3.6, and the Care Planning Practice
Guide.
5.3.7 Care planning in other groups with externally 
co-ordinated care
Some other groups of individuals require particular co-ordination
of care with other agencies.
Individuals with severe mental health problems whose care is co-
ordinated under the care programme approach (CPA), particularly
those on “enhanced” CPA, will have a named mental healthcare
co-ordinator. The structured drug treatment providers usually
contribute to elements of the mental health CPA plan of care.
Those who are under supervision or treatment orders from the
criminal justice system will need careful integration of planning of
their structured treatment to optimise outcomes (e.g. in the case
of those on Drug Rehabilitation Requirements). The probation
service may have information (particularly regarding risk issues
and offending behaviour) that may need to be incorporated into
the care plan.
Clients receiving community care funding, with a community care
manager (sometimes drug specific) responsible for their treatment
(e.g. someone in residential rehabilitation), may have the co-
ordination of care and case management provided by a
community care manager (sometimes drug-specific). The drug
service interventions and care plan will then be provided in the
context of that formal process of planning care.
In these, and other similar cases, a decision will still need to be
made about the level of planning and monitoring required by the
provider of the structured drug treatment, and the care plan will
need to reflect arrangements for contributing to the external plans
of care.
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6 Integrated care pathways
6.1 Commissioning integrated care pathways
An integrated care pathway (ICP) describes the nature and
anticipated course of treatment for a particular client and a
predetermined plan of treatment. A system of care should be
dynamic and able to respond to changing individual needs over
time. It should also be able to provide access to a range of
services and interventions that meet an individual’s needs in a
comprehensive way. Previous consultation has shown that the
majority of respondents found that the ICPs set out in Models of
Care 2002 had been useful to them in their work.
ICPs should be developed for drug and alcohol misusers for the
following reasons:
• Drug and alcohol misusers often have multiple problems that
require effective co-ordination of treatment
• Several specialist and generic service providers may be
involved in the care of a drug and alcohol misuser
simultaneously or consecutively
• A drug and alcohol misuser may have continuing and evolving
care needs requiring referral to services providing different tiers
of intervention over time
• ICPs ensure consistency and parity of approach nationally (i.e.
a drug misuser accessing a particular treatment intervention
should receive the same response wherever they access care)
• ICPs ensure that access to care is not based on individual
clinical decisions or historical arrangements.
Models of Care 2002 Part 2 encouraged commissioners and
providers to develop and publish local ICPs by March 2004. ICPs
may need to be revised in the light of this update and in the light
of changes in treatment systems (particularly in relation to
offenders), changes for clients requiring Tier 4 treatment and for
those requiring active interventions for prevention or management
of blood-borne virus infection.
6.2 Elements of integrated care pathways
Commissioners should ensure that each drug and alcohol
treatment intervention should have an ICP, which should be
agreed with and between local providers, and built into service
specifications and service level agreements. Integrated care
pathways should contain the following elements:
• A definition of the treatment interventions provided 
• Aims and objectives of the treatment interventions 
• A definition of the client group served 
• Eligibility criteria (including priority groups) 
• Exclusions criteria or contraindications 
• A referral pathway 
• Screening and assessment processes 
• Development of agreed treatment goals 
• A description of the treatment process or phases 
• Co-ordination of care 
• Departure planning, aftercare and support 
• Onward referral pathways 
• The range of services with which the interventions interface.
These elements are designed to provide clarity as to the type of
client the drug treatment intervention caters for, what the client
can expect treatment services to provide, and the roles and
responsibilities of the service within the integrated care system
and towards the individual client.
6.3 ICPs and the treatment journey
An ICP will not necessarily be the whole description of a person’s
treatment journey. An individual ICP will be focused on one
treatment intervention in a client’s care plan, within which a client
may receive a range of interventions. Therefore, it is important that
the development of local ICPs takes into account the client
treatment journey through care-planned treatment and represents
it in a way that clients can understand and see their experience
reflected.
Figure 2 sets out an overall representation of client’s journey
through treatment. This can assist with the planning of ICPs.
However, this figure and the ICPs for drug treatment described in
Models of Care 2002: Part 2 are illustrative rather than
prescriptive. Local ICPs should describe the structure and content
of drug treatment interventions, but these should be adapted to
local needs and drug treatment providers as appropriate.
As well as ICPs for specific treatment types, there will also need
to be local ICPs developed for specific client groups, particularly
excluded groups of service users who may have difficulty in
gaining access to treatment because they have complex needs
and because they are vulnerable. Models of Care 2002: Part 2
has some examples of these (e.g. ICPs for drug and alcohol
misusing parents and pregnant drug users). Again, these must be
developed using the above principles to fit in with local need.
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7 Quality criteria and 
improvement reviews
Drug treatment should be seen as integral to the NHS and other
social care and criminal justice provision. Realising links to other
quality initiatives is important, as the majority of drug misuse
treatment will be commissioned by local mechanisms for
commissioning healthcare. Primary care trust commissioning
structures and local joint commissioning structures and
partnerships are crucial to drug treatment.
7.1 The Department of Health’s 
Standards for Better Health
Drug treatment should be provided in line with the Department of
Health’s Standards for Better Health (2004). The purpose of the
standards is to provide a common set of requirements applying
across all healthcare organisations, to ensure that health services
are safe and of an acceptable quality and provide a framework for
continuous improvement.
There are two sets of standards: 
• Core standards describe a level of service that is acceptable
and must be universal. Meeting the core standards is
mandatory. Healthcare organisations must comply with them
from the date of publication
• Developmental standards are designed for a world in which
patients’ expectations are increasing. Progress is expected to
be made against the developmental standards across much
of the NHS as a result of the NHS Improvement Plan and the
extra investment in the period to 2008. The Healthcare
Commission will, through its criteria for review, assess
progress by healthcare organisations towards achieving the
developmental standards.
These standards cover seven domains – safety, clinical and cost-
effectiveness, governance, patient focus, accessible and
responsive care, care environment and amenities and public
health. The Healthcare Commission will focus assessments
around these performance areas to measure outcomes, outputs
and process quality.
Models of Care: Update 2006 specifically supports service
development towards development standard D2.
Standard D2: Patients receive effective treatment and care
that:
• Conforms to nationally agreed best practice, particularly as
defined in the national service frameworks, NICE guidance,
national plans and agreed national guidance on service
delivery
• Takes into account their individual requirements and meets
their physical, cultural, spiritual and psychological needs and
preferences
• Is well co-ordinated to provide a seamless service across all
organisations that need to be involved, especially social care
organisations
• Is delivered by healthcare professionals who make clinical
decisions based on evidence-based practice.
7.2 NTA and Healthcare Commission 
Improvement Reviews
The NTA works in partnership with the Healthcare Commission,
developing detailed criteria for reviewing drug and alcohol
treatment services, and carrying out these reviews. These criteria
are developed during the process of each themed annual
Improvement Review of drug treatment systems. Improvement
Reviews will review local providers and commissioning functions
against these criteria and against Standards for Better Health
(2004). 
The reviews for 2005/06 were piloted and developed in
consultation with the drugs field. Detailed criteria have been
developed for reviewing care planning and co-ordination and
community prescribing, and were published in 2005. They are
available on the NTA website at www.nta.nhs.uk. Criteria for future
reviews will also be available from the NTA website.
Upcoming themes are:
• 2006/07: systems management (across the key elements of
risk management, patient choice, diversity and effective
partnerships) and harm reduction provision
• 2007/08: Tier 4 treatment and diversity (to be confirmed). 
There are two parts to an Improvement Review. In the first part,
the performance of all organisations taking part in the review is
assessed. Using a standard framework, an initial assessment is
made of the performance of each DAT and participating
healthcare organisation. Wherever possible, this is done using
nationally held data to reduce the burden on treatment providers.
In the second part, the minority of organisations or treatment
systems (approximately ten per cent) that have the weakest
assessments are helped in developing an action plan to improve
their performance.
The assessments are focused on a small number of key
outcomes and quality measures, which matter most to patients
and the public, and on the key features of services that are
necessary to achieve good outcomes and quality for patients and
the public.
More detailed information on the review process can be found on
the NTA website at www.nta.nhs.uk and the Healthcare
Commission website at www.healthcarecommission.org.uk.
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7.3 National standards for professionals 
working in drug services
A range of quality frameworks are relevant and used by drug
treatment services to demonstrate quality or meet national
requirements for registration or inspection. These include the
following:
7.3.1 NHS Knowledge and Skills Framework
The NHS Knowledge and Skills Framework (NHS KSF)41 defines
and describes the knowledge and skills which NHS staff need to
apply in their work in order to deliver quality services. It provides a
single, consistent, comprehensive and explicit framework on
which to base review and development for all staff. The NHS KSF
and its associated development review process lie at the heart of
the career and pay progression strand of the NHS Agenda for
Change. Specific professional registration criteria and
qualifications or accreditation programmes exist for groups such
as nurses, pharmacists, general practitioners and addiction
psychiatrists involved in substance misuse treatment, which relate
to differing levels of competence. These involve accreditation by
the Nursing and Midwifery Council, the Royal Pharmaceutical
Society of Great Britain (RPSGB), the General Medical Council,
the Royal College of General Practitioners and the Royal College
of Psychiatrists and most recently additional training and
accreditation for supplementary non-medical (nurse and
pharmacist) prescribers. The Royal College of General
Practitioners and the Royal College of Psychiatrists, in conjunction
with the NTA, published a set of competences for doctors in
2005.31
7.3.2 Drugs and Alcohol National Occupational
Standards
The Drugs and Alcohol National Occupational Standards
(DANOS) guidance gives clear descriptions of the standards of
performance required of people in the drugs and alcohol field. The
guidance also describes the knowledge, understanding and skills
workers need in order to perform to those standards. The
DANOS standards describe all the functions and activities
involved in improving the quality of life for individuals and
communities by minimising harm associated with substance
misuse. There are three key categories in DANOS: service
delivery, management of services and commissioning services.
More information on DANOS, and the standards, can be found at
www.skillsforhealth.org.uk/danos.
Training providers increasingly provide programmes which are
linked to National Occupational Standards, which will assist
employers to ensure new workers can be quickly inducted and
existing workers can be provided with the knowledge and skills
needed to perform their roles competently.
7.3.3 National minimum standards for care homes for
younger adults
The national minimum standards for care homes for younger
adults42 were issued under the Care Standards Act 2000 (CSA).
The Commission for Social Care Inspection (CSCI) currently has
the remit to inspect and regulate individual establishments,
agencies and institutions for which registration as care homes is
required. The standards specifically apply to care homes for
people with alcohol or substance misuse problems and cover
choice of home, individual needs and choices, lifestyle, personal
and healthcare support, concerns, complaints and protection,
environment, staffing, conduct and management of the home.
They also specify the national occupational standards for staff. In
order to meet registration criteria, staff and managers are required
to have relevant TOPSS NVQ qualifications, or demonstrate they
are working towards them.
7.3.4 Commissioning Standards for Drug and Alcohol
Treatment and Care
In 1999, the Substance Misuse Advisory Service (SMAS), on
behalf of the Department of Health, developed the
Commissioning Standards for Drug and Alcohol Treatment and
Care43 document as a tool for commissioners of drug treatment.
The document provides guidance on the commissioning of
comprehensive and evidence-based alcohol and drug treatment
and care systems, and is available on the NTA website at
www.nta.nhs.uk.
7.3.5 Quality in Drugs and Alcohol Services (QuADS)
QuADS44 was developed jointly by Alcohol Concern and
DrugScope for the DH (1999) and is still widely used by alcohol
and drug treatment services throughout England as the set of
quality standards for organisations in the sector. Organisations
use the standards for self-assessment and also for peer review.
QuADS is particularly relevant when considering the management
and quality assurance of drug and alcohol treatment services.
7.3.6 Other quality frameworks and standards
Other quality improvement frameworks, standards or accreditation
systems are also be relevant to alcohol intervention and treatment
systems. These may include clinical governance mechanisms in
NHS providers, Investors in People, criminal justice accredited
programmes, standards and registration for independent hospital
provision, and RPSGB standards as set out in the Medicines,
Ethics and Practice guidance.45
Commissioners and providers should be clear about which quality
initiatives are required and how other quality initiatives (e.g.
Investors in People), can contribute to demonstrating the quality
of local provision. Commissioners should minimise duplication of
effort for providers in reporting requirements where possible.
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7.4 Quality requirements for drug treatment
The following section outlines criteria to summarise key quality
requirements for drug treatment that represents nationally agreed
best practice, consistent with this guidance and with other
nationally recognised guidance. Therefore, these can be used to
support commissioners, services, and the Healthcare
Commission in making progress in achieving a number of
developmental standards in drug misuse treatment.
There are 15 key quality criteria for drug treatment outlined. The
quality criteria are divided into two sections: those for
commissioners, and those for providers of drug treatment. The 15
broad quality criteria for drug treatment are:
7.4.1 Quality requirements for commissioners
QRC1: Strategic partnerships
Local commissioning mechanisms should have formal strategic
partnerships with key stakeholders including health, social care,
housing and employment services, drug treatment providers, and
local drug user and carers.
QRC2: Local needs assessments
There is a shared understanding of the local need for drug
treatment, based upon annual needs assessment reports in line
with a nationally agreed methodology. The needs assessment
profiles the diversity of local need for drug treatment, including
rates of morbidity and mortality (e.g. infection with BBVs), the
degree of treatment saturation or penetration, and impact of
treatment on individual health, public health and offending.
QRC 3: Drug treatment systems are developed in line with
national frameworks
Local commissioners for drug treatment develop local drug
treatment system plans annually in line with the Models of Care:
Update 2006, with focus on reducing harm to individuals and
communities, improving clients’ journeys through treatment,
predicting client flow through local systems and improving the
effectiveness of local drug systems.
QRC 4: Local commissioning partnerships demonstrate good
practice in managing public finance and contracts
Local commissioners demonstrate best practice in handling
public money, contracting with providers and monitoring service
level agreements.
QRC 5: Performance management of local drug treatment
systems
Local commissioning partnerships performance manage local
systems of drug treatment using data and key performance
indicators in partnership with local strategic partners and plans.
QRC 6: Local commissioning functions are “fit for purpose”
and competent
Local commissioning partnerships are “fit for purpose”, have
involvement from key stakeholders at an appropriate level of
seniority and ensure commissioners are competent against
national quality standards and other relevant professional
frameworks.
7.4.2 Quality requirements for providers
QRP 1: A person-centred service
All those with drug misuse problems have access to appropriate
drug treatment irrespective of their background and
characteristics and each service user is supported to improve
their health, social circumstances and wellbeing by the provision
of individually tailored drug treatment.
QRP 2: Screening and assessment
Individuals with drug misuse problems are screened and/or
assessed in sufficient detail to identify their drug treatment needs
and inform individual care plans (where required). 
QRP 3: Reducing harm to drug misusers
Individuals with drug misuse problems receive information, advice,
injecting equipment where appropriate and brief interventions and
treatment to help them reduce potential harm due to the
transmission of blood-borne viruses (HIV, hepatitis B and C), drug-
related infections and overdose, and other drug related deaths,
and to improve their physical and mental health
QRP 4: Reducing drug-related harm to others 
• Drug treatment providers ensure that drug service users’
significant others have access to support and interventions to
reduce harm related to drug misuse. This includes intervening
to reduce the risk of (significant) harm to the children of drug
misusers and ensuring partners and families of service users
have access to support in their own right
• Drug treatment providers collaborate with criminal justice
colleagues to ensure drug-misusing offenders have access to
appropriate drug treatment, and appropriate interventions
addressing risk of harm
• Drug treatment providers work with local authorities and
communities to minimise other, potential drug related harm,
e.g. discarded injecting equipment and public nuisance
• Drug treatment providers work within Area Child Protection
Committee guidelines
QRP 5: Providing brief interventions
Brief drug-related interventions are provided to drug misusers, as
required, to address drug and alcohol problems (e.g. for some
cannabis misuse problems), to increase access to and motivation
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for structured treatment, and to reduce drug or alcohol related
harm (as appropriate). 
QRP 6: Improving engagement with structured drug
treatment 
Access to structured drug treatment should be within national
waiting times for drug treatment and those accessing structured
drug treatment should usually be retained for at least 12 weeks.
QRP 7: Structured treatment delivery: A care planning
approach to deliver positive change in clients’ lives 
All individuals in structured drug treatment have an identifiable
written care plan, which tracks their progress and is regularly
reviewed. Clients in drug treatment should show measurable
positive change while in drug treatment across a range of
domains. This should include: less illegal drug misuse; better
health; less risk of infection and transmission of BBVs, reduced
risk of behaviours associated with overdose; fewer drug-related
offences committed; better social functioning and evidence of
reintegration into the community.
QRP 8: Improving reintegration and treatment completion 
Service users who need to remain in structured treatment are
retained while achieving improvements in their health and social
functioning. Service users who can progress out of drug
treatment are supported to complete treatment via a planned exit
with aftercare support. Drug services have defined pathways to
enable service users to integrate into the community during and
following the completion of treatment, including access to
appropriate housing, education, employment and mainstream
health.
QRP 9: Provision of aftercare and reintegration
All those that have left structured drug treatment should have
access to drug-related support and mutual aid groups. This
should include easy access back to structured drug treatment in
the case of relapse.
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8 Performance monitoring and
management
8.1 Monitoring drug treatment 
8.1.1 NDTMS
Structured drug treatment (apart from treatment in prisons) is
monitored through the National Drug Treatment Monitoring
System (NDTMS). This system involves the process of collecting,
collating and analysing information from the drug treatment sector.
There is an NDTMS centre to cover each region, with the majority
being hosted by public health observatories. One regional centre
is housed within a mental health trust, while two regions are
hosted by the NTA. The purpose of the NDTMS centres is to
obtain accurate, good-quality, timely information for reporting
structured drug treatment activity
8.1.2 Numbers in treatment and retained in treatment
Through the NDTMS, the NTA monitors the performance of the
structured drug treatment system at national and regional level. It
reports on the numbers of people in contact with services
providing structured drug treatment, and those retained for 12
weeks or more – this data is required so performance can be
measured against the national target. A detailed breakdown of the
data collected on clients in treatment is published in the form of
an annual report on the NTA website at www.nta.nhs.uk.
8.1.3 Waiting times
Until March 2006, quarterly reported waiting times figures have
been based on DAT partnership self-reports. However, from April
2006 figures will be reported via NDTMS.
Since January 2006, the NTA has been publishing a range of
monthly drug treatment performance data, including numbers in
treatment and numbers retained in treatment for over 12 weeks.
The NDTMS website will make available an increasing amount of
regularly published performance data (including waiting times)
throughout 2006/07. See www.ndtms.net for more details.
8.1.4 Minimising the data collection burden
As a matter of principle, commissioners should endeavour to use
NDTMS (and other nationally collated data such as DIRWeb)
wherever possible, in service level agreements and performance
monitoring with providers. This is to minimise requirements on
providers to collect and provide two different sets of data.
8.2 Performance management of drug treatment
8.2.1 NHS local delivery plans
Local delivery of National Health Service priorities is ensured via
the local delivery plan process. The LDP contains all the
Government’s PSA targets on health, including drug misuse, and
is the key vehicle for the local PCT to set its priorities for
improving health, developing services and involving local people
and agencies in the planning and delivery of healthcare. PCT
plans for increasing the numbers of drug misusers accessing and
retained in structured treatment are aggregated with the plans of
other PCTs within a strategic health authority (SHA) area to form
their overall LDP for increasing the numbers in treatment and
improving retention.
On top of the PSA targets, DAT partnerships and the NTA have
agreed local “stretch targets”, which are intended to better reflect
local situations and need. The PCT and the SHA have included
these stretch targets in their planning.
The SHAs are performance managed by the Recovery and
Support Unit (at the Department of Health) and, in turn, the SHAs
performance manages PCTs to ensure they meet the targets set.
The plans must ensure year-on-year increases in numbers of drug
users entering treatment and drug users retained in treatment for
12 weeks or more.
Details of local numbers in treatment and retention targets are
available from SHAs and PCTs. Contact details for these can be
found at the NHS website www.nhs.uk 
8.2.2 Healthcare Commission performance ratings
The Healthcare Commission provides an independent
assessment of the extent to which primary care trusts and
provider trusts perform against national targets as part of the
annual health check. In 2006/07, the following assessments will
be made:
• PCTs: Performance against LDP of “in treatment” and
“percentage retained in treatment” figures
• Mental health trusts: The improvement over the previous
year of the “percentage retained in treatment” figure 
• Acute trusts: A process indicator looking at screening,
advice, information and referral.
More information on these indicators, including detail on the
measurements and data required, is set out on the Healthcare
Commission’s website at www.healthcarecommission.org.uk.
8.2.3 NTA performance management
Drug treatment monitoring data is used by NTA regional teams to
performance manage and support local DAT partnerships in
achieving the targets agreed in their annual adult drug treatment
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plans. The DAT partnership should develop strategies through the
treatment planning process to achieve year-on-year increases in
the numbers of people entering treatment, improvements in the
percentages of clients retained in treatment for 12 weeks or more,
improved waiting times, and other locally relevant partnership
performance expectations.
Draft treatment plans are submitted to NTA regional teams, who
work with the DATs to refine these plans in the light of available
resources, local assessments of need, and consultation with
regional partners such as SHAs, the regional offender manager
and public health bodies. The plans agreed with each DAT are
used by the NTA to help monitor the progress of drug treatment
at a local and regional level. The NTA fulfils the performance
management role on these targets alongside the SHAs and other
local and regional partners in performance managing the plans set
by DAT partner organisations on targets, including those on
numbers in treatment and client retention.
The monitoring of targets, though important, is part of a more
complex performance management process. NTA teams work
with partnerships to arrive at a better understanding of need using
available data – determining treatment saturation (i.e. how many
of those potentially in need of treatment are in the treatment
system) and having a knowledge of treatment flow (i.e. numbers
in treatment, retained in treatment and exiting treatment through
planned exits from the system). A range of stakeholders, including
service providers, and users and their carers, help to inform and
define this process.
The NTA makes the first part of each DAT partnership’s adult drug
treatment plan (Part 1: Strategic Summary, National Targets,
Partnership Performance Expectations and Funding Profile)
publicly available via its website, www.nta.nhs.uk.
8.2.4 NTA and Healthcare Commission Improvement
Reviews
The NTA and Healthcare Commission Improvement Reviews will
contribute to the performance management of drug treatment.
These reviews use a range of data to rate DAT partnerships
against specific criteria. This includes data from NDTMS, annual
audit information, bespoke data compiled specifically for the
review process, and other existing data sources (e.g. the NTA’s
prescribing audit).
Each DAT partnership is sent a report with their performance
scores and the detail behind them, from the assessment and
scoring done by the NTA and the Healthcare Commission. The
scoring is based on a range of data collected for the assessment
framework and scores for each criterion are worked out by
applying pre-determined rules.
For more on the process of Improvement Reviews, see section
9.2 and the NTA website www.nta.nhs.uk.
The DATs and healthcare organisations (around ten per cent) that
have the weakest assessments will be asked to create action
plans to address performance problems identified in the
assessment, unless they already have convincing action plans in
place. NTA regional teams will work with the Healthcare
Commission and DATs to improve the performance of these
DATs.
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9 Drug treatment interventions
9.1 Drug treatment interventions as 
part of a local treatment system
The following section outlines the key drug treatment interventions
and describes how they fit into the local treatment system. The
NTA has clarified and defined the specific drug treatment
interventions to assist a common understanding. These definitions
below are consistent with Models of Care 2002 but provide
additional clarity and a summary of key issues. They are also
updated to reflect new guidance materials e.g. DANOS and Roles
and Responsibilities of Doctors in the Provision of Treatment for
Drug and Alcohol Misusers (2005).30 This section should be read
in conjunction with the sections on care planning and the
treatment journey, and integrated care pathways.
Specific interventions in local treatment systems should combine
to form the client’s treatment journey. The integrated care
pathways for each intervention should be designed in a way that
ensures good links across a range of interventions can be made
effectively to provide joined-up treatment for each client.
Commissioners should ensure that the full range of these
treatment interventions are available to clients in their DAT
partnership area, according to identified local need. These
separate interventions need to fit together in a complementary
way, as part of a local drug treatment system.
Some of these interventions are open access (i.e. advice and
information, harm reduction interventions) and should be available
and accessible for all people with drug problems in a particular
area. However, these may also be component parts of a client’s
care plan, and are therefore delivered as part of structured
treatment. The other interventions included in this chapter (apart
from aftercare) are “structured treatment” interventions and have
to be delivered as part of a coherent care plan agreed between
the client, their keyworker and other practitioners involved in
delivery.
A client may receive a number of these interventions as identified
by their care plan, either sequentially (e.g. inpatient treatment
followed by residential rehabilitation) or concurrently (e.g. specialist
prescribing alongside psychosocial interventions and harm
reduction interventions).
9.2 Substance misuse related advice and information 
Drug and alcohol (substance misuse) related advice and
information interventions should provide appropriate advice and
accurate up-to-date information on a range of substance misuse
related issues, including: 
• Information about different drugs and alcohol, and their effects
• Advice about stopping misuse of drugs and alcohol
• Information on how to reduce the potential harm from drug
misuse (e.g. safer injecting and reducing overdose risks) 
• How and where to access help for drug problems
• How and where to access help for other problems (e.g.
housing and sexual health)
• Information for clients’ carers, partners and family members
on drug problems and treatment.
The information provided must be accessible and meaningful to
the recipient (e.g. using appropriate language, and written at a
suitable literacy level), and if possible, available in alternative
formats if required.
Advice and information interventions should be available to all
substance misusers on an open-access basis, and may be
provided by treatment services providing interventions across all
four tiers. Commissioners should ensure that advice and
information is available across a range of treatment interventions.
The provision of drug related advice and information may be
incorporated into a client’s care plan.
Open access drug and alcohol advice and information services
need to be commissioned to work closely with generic
mainstream services – for example, they could be commissioned
to provide training and information to non-specialist services to
ensure they have up-to-date information, and that staff in
mainstream services are able to adequately deliver drug-related
advice and information.
9.3 Harm reduction interventions 
In their broadest sense, harm reduction policies, programmes,
services and actions work to reduce the health, social and
economic harms to individuals, communities and society that are
associated with the use of drugs (UKHRA, 2005).46
A harm reduction approach recognises that a valid aim of drug
interventions is to reduce the relative risks associated with drug
misuse, by a range of measures such as reducing the sharing of
injecting equipment, support for stopping injecting, provision of
substitution on opioid drugs for heroin misusers and support for
abstinence from illegal drugs.
Harm reduction interventions should be integrated into all drug
treatment service specifications via contracts or service level
agreements, so that harm reduction interventions are available at
the full range of locally commissioned treatment services. Harm
reduction interventions should also be integrated into structured
drug treatment according to an individual client’s needs and
should be incorporated into a care plan agreed with the client.
Most harm reduction interventions specifically aim to prevent
diseases due to blood-borne virus (BBV) infections (most
particularly HIV and viral hepatitis infections) and other drug-
related harm, including overdose and drug-related death. All drug
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treatment services, residential or community based, should
provide as part of core treatment, distinct harm reduction
interventions aimed at reducing the spread of BBVs and risk of
drug-related deaths.
Specific harm reduction interventions to reduce the spread of
blood-borne viruses and reduce overdose include:
• Needle exchange services – the provision and disposal of
needles and syringes and other clean injecting equipment
(e.g. spoons, filters, citric acid) in a variety of settings
• Advice and support on safer injection, on reducing frequency
of injecting and on reducing initiation of others into injecting
• Advice and information to prevent transmission of BBVs
(particularly hepatitis A, B and C, and HIV) and other drug
misuse-related infections
• Availability of advice, information and counselling, as
appropriate, for viral hepatitis and HIV testing (pre and post
test)
• Access to testing for blood-borne viruses
• Provision of hepatitis B vaccination 
• Provision of hepatitis A vaccination if appropriate
• Access to assessment and treatment for hepatitis B, C and
HIV infection
• Counselling relating to HIV testing (pre and post test)
• Advice and support on preventing risk of overdose and drug-
related death
• Risk assessment and referral to other treatment services.
Harm reduction interventions such as needle exchange, advice
and information on safer injecting, reducing injecting and
preventing overdose should also be available as open-access
services in each local area. These are available as part of
specialist statutory sector drug treatment services, voluntary
sector services and pharmacy needle exchanges. Needle
exchange services often have contact with drug misusers who
are not in touch with structured drug treatment services.
Guidance on what services should be available from pharmacy
needle exchanges is available in Best Practice Guidance for
Commissioners and Providers for Pharmaceutical Services for
Drug Users (NTA, 2006).47 Advice and information on harm
reduction should also be available to carers of drug users, as
appropriate.
The Department of Health has recently done work on raising the
awareness of risks, detection and treatment of hepatitis B and C.
In 2004, primary care trusts were required to use, as standard, a
combination of treatments for hepatitis C with fewer side-effects
than older treatments, which has been found to be effective in
clearing the infection in a substantial proportion of cases. See the
Chief Medical Officer’s Update Number 39, August 2004.48
The National Institute for Health and Clinical Excellence (NICE) has
produced a guidance document on treatment for people with
hepatitis C: Guidance on the Use of Ribavirin and Interferon Alpha
for Hepatitis C (NICE, 2000).49
The Department of Health has published Hepatitis C: Guidance
for Those Working With Drug Users (2001),50 which gives
information on hepatitis C and on approaches to prevention and
management that is of relevance to provider services and
commissioners, and which is due to be updated in 2006.
Drug treatment commissioners should liaise with hepatitis C
treatment commissioners to ensure adequate provision of
Hepatitis C treatment for drug misusers. Drug treatment
commissioners should also liaise and develop agreements with
mainstream non-specialist services (e.g. A&E, liver disease units,
HIV services), to ensure that people who have been at risk of
exposure to hepatitis B through injecting drugs have access to
testing, and arrangements are in place within the PCT area for the
immunisation of drug users. Immunisation programmes should be
targeted and need to be accessible to current injectors, those at
risk of becoming injectors and close contacts (e.g. sexual
partners), who may be at risk.
9.4 Community prescribing interventions:
GP prescribing and specialist prescribing 
Community prescribing involves the provision of care-planned
specialised drug treatment, which includes the prescribing of
drugs to treat drug misuse. The range of community prescribing
interventions can include the following:
• Stabilisation on substitute opioids, including dose titration
• Prescribing for a sustained period to substitute illicit drugs,
such as methadone and buprenorphine (maintenance
prescribing)
• Prescribing for withdrawal from opioids with opioid or non-
opioid medications such as buprenorphine or lofexidine
(community detoxification)
• Prescribing to prevent relapse
• Stabilisation and withdrawal from sedatives, such as
benzodiazepines
• Prescribing for assisted withdrawal from alcohol where
appropriate
• Treatment for stimulant users, which may include symptomatic
prescribing
• Non-medical prescribing (by nurses or pharmacists).
All prescribing interventions must be carried out in line with Drug
Misuse and Dependence – Guidelines on Clinical Management
(DH, 1999),21 also known as the “clinical guidelines” or the
“orange book”. Attention should also be paid to the forthcoming
(2007) NICE guidelines on opiate detoxification, and the NICE
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technology appraisals of methadone and buprenorphine (for
opiate maintenance treatment) and of naltrexone (for relapse
prevention). The “clinical guidelines” will be updated alongside the
development of the NICE work for 2007.
Substitute prescribing alone does not constitute drug treatment
(NTA expert prescribing group, 2002). A community prescribing
intervention should be provided within a care-planned package of
care with an identified keyworker. It should be aimed at
addressing the range of identified needs. The care plan should
address drug and alcohol misuse, health needs, offending
behaviour and social functioning. Interventions to tackle drug
misuse problems may include:
• Hepatitis B vaccination and HIV and hepatitis testing
• Treating drug-related infections, e.g. abscesses
• Harm reduction and health promotion interventions e.g.
overdose prevention, use of naloxone, sexual health advice
and needle exchange
• Provision of, or access to, psychosocial interventions and
support, e.g. motivational interventions.
The care plan may also include interventions to tackle problems in
the other domains, and may include:
• Provision of, or access to, interventions to address other
psychological health needs, or mental health needs 
• A range of abstinence-oriented interventions e.g. mutual
support groups (including 12-Step)
• Assisting with access to suitable housing, employment,
education and training opportunities, and childcare, as
required.
The keyworker is responsible for ensuring that all components of
the community prescribing treatment programme work together
to help clients achieve the goals set out in their care plans.
There are a number of treatment settings where community
prescribing takes place, which can be broadly grouped as GP
prescribing and specialist prescribing.
Commissioners should ensure local treatment systems have a
complete spectrum of medical provision to meet the range of
needs and numbers of substance misusers. This requires a
variety of skills and competences at various levels, from general
medical skills to GPs offering less complex drug treatments under
enhanced contracts, to specialist addictions skills and addiction
psychiatry skills. This is a key message arising from the
consensus document produced by the Royal College of General
Practitioners and Royal College of Psychiatrists’ Roles and
Responsibilities of Doctors in the Provision of Treatment for Drug
and Alcohol Misusers (2005),30 as summarised in an NTA briefing
note on the NTA’s website. www.nta.nhs.uk.
9.4.1 GP prescribing
GP prescribing is community prescribing for drug misuse which
may be carried out in a primary care setting through a primary
healthcare team, consisting of GPs and other primary care staff
(depending on contractual arrangements). This is normally
assisted or supported by a specialist drug team. The clinical
guidelines advise against GP prescribing without such support.
A number of models of primary care drug treatment have evolved
in the context of local resources and identification of need. These
models include various types of shared care services in which GP
services are supported by more specialist service provision, and
primary care-led drugs services which do not have shared care
arrangements with a secondary care provider. For more details on
these, see section 3.5.4.
GP prescribing should be provided within a care plan with regular
keyworking, and provision of appropriate psychosocial or other
interventions as required. Different degrees of care planning may
be appropriate in different primary care arrangements (NTA/RCGP
2004)51. The care plan should also address drug and alcohol
misuse, health needs, offending behaviour and social functioning.
In some practices, the GP will assume the keyworker role, but
more commonly the shared care or primary care worker will take
on this responsibility in collaboration with the GP. For more on
care planning in primary care, see the Care Planning Practice
Guide.
GP prescribing should be guided by the Department of Health’s
clinical guidelines. These cover arrangements for daily dispensing,
for shared care support and for the provision of supervised
consumption through community pharmacies.
The client group in primary care has traditionally been drug users
who are stable on substitute medication or whose problem level is
mild to moderate. However, the exact nature of the clients treated
and how the prescribing takes place will depend on the skills and
competences of the GP and the degree of skilled multidisciplinary
support. The guidance document Roles and Responsibilities of
Doctors in the Provision of Treatment for Drug and Alcohol
Misusers (2005) specifies a hierarchy of roles for GPs, with
increasing competency levels: 
• GPs providing core services 
• GPs providing enhanced services
• GPs with special clinical interest (GPwSI) providing enhanced
services
• Substance misuse specialist (primary care).
These competency levels are described in more details in section
3.5 
GP prescribing services may also be supported by non-medical
prescribers, such as nurses and pharmacists, as well as other
staff who are competent to provide drugs interventions, such as
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harm reduction, interventions for blood-borne viruses and
psychosocial interventions.
9.4.2 Specialist prescribing
Specialist prescribing is community prescribing for drug misuse in
a specialist drug service setting, which normally comprises a
multidisciplinary substance misuse team. Specialist prescribing
interventions normally include comprehensive assessments of
drug treatment need and the provision of a full range of
prescribing treatments in the context of care-planned drug
treatment. The specialist team should also provide, or provide
access to, a range of other care-planned healthcare interventions
including psychosocial interventions, a wide range of harm-
reduction interventions, BBV prevention and vaccination, and
abstinence-oriented interventions.
The client group should be comprised of drug misusers whose
problem level is mostly moderate to severe.
The teams include specialist doctors who are usually consultant
addiction psychiatrists “with a Certificate of Completion of Training
(CCT) in psychiatry, with endorsement in substance misuse
working exclusively to provide a full range of services to
substance misusers”. Such teams sometimes have other
specialists including: 
• Consultants in general psychiatry with a special interest in
addiction
• Consultants in general psychiatry
• Other doctors on the specialist register (associate specialists)
• Senior clinical medical officers (see Roles and Responsibilities)
• Doctors in training.
Since the specialist team should provide or enable access to
other drug-related interventions identified in the client’s care plan,
the team may contain a range of staff including clinical
psychologists, counselling psychologists, general and psychiatric
nurses, pharmacists, social workers and drug workers.
Specialist prescribing services may also be supported by non-
medical prescribers, such as nurses and pharmacists). For more
information on nurse prescribing, see Nurse Prescribing in
Substance Misuse (NTA, 2005)52 – this will be updated in 2006 to
include pharmacists and will issued as guidance on non-medical
prescribing in substance misuse. Further guidance on prescribing
for pharmacists is available in the RPSGB’s Clinical Governance
Framework for Pharmacist Prescribers and Organisations
Commissioning or Participating in Pharmacist Prescribing.53
9.5 Structured day programmes 
The term “structured day programmes” replaces the old term
“structured day care” and will be the intervention name used for
NDTMS monitoring from April 2006. Introduction of an additional
category of “other structured treatment” can be used for less
extensive or less structured “day care” provided in the context of
a structured care plan (see section 9.7 for further discussion).
Structured day programmes (SDPs) provide a range of
interventions where a client must attend 3–5 days per week.
Interventions tend to be either via a fixed rolling programme or an
individual timetable, according to client need. In either case, the
SDP includes the development of a care plan and regular
keyworking sessions. The care plan should address drug and
alcohol misuse, health needs, offending behaviour and social
functioning.
SDPs usually offer programmes of defined activities for a fixed
period of time. Clients will usually attend the programme
according to specified attendance criteria, and follow a set
timetable that will include group work, psychosocial interventions,
educational and life skills activities. Some clients may be attending
the SDP as a follow-on or precursor to other treatment types, or
may be attending as part of a criminal justice programme
supervised by the probation service (e.g. DRR), or community
rehabilitation.
Settings: SDPs are normally community-based services, set in
centres that have been specifically designated for the programme
(purpose-built or converted) and have rooms designated for
specific parts of the programme (e.g. group work and life skills).
They may be attached to other drug treatment services if they are
part of a larger treatment agency. Structured day programmes are
also used in prisons, and in prisons the majority of drug treatment
programmes would fall into this category.
9.6 Structured psychosocial interventions 
The term “structured psychosocial interventions” replaces the old
term “structured counselling” and has been the intervention name
used for NDTMS monitoring since April 2006. Introduction of an
additional category of “other structured treatment” allows use of
this term for less clearly defined counselling in the context of a
structured care plan (see the relevant section below for further
discussion).
Structured psychosocial interventions are clearly defined,
evidence-based psychosocial interventions, delivered as part of a
client’s care plan, which assist the client to make changes in their
drug and alcohol using behaviour. These interventions are
normally time limited and should be delivered by competent
practitioners. Competent practitioners will have adequate training,
regular clinical supervision to ensure adherence to the treatment
model and be able to demonstrate positive client outcomes.
Structured psychosocial interventions should be identified within a
care plan. These interventions can be delivered in individual or
group settings, and by any practitioners who have appropriate
training and supervision. A number of these interventions can be
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developed and delivered through use of protocols to improve
consistency and ease of delivery.
Evidence-based psychosocial interventions include: 
• Cognitive-behaviour therapy (CBT)
• Coping skills training 
• Relapse prevention therapy
• Motivational interventions 
• Contingency management 
• Community reinforcement approaches 
• Some family approaches.
Psychosocial treatment skills (e.g. particular relapse prevention
techniques) may be used in face-to face sessions (e.g. by a
keyworker), but this would not reach the threshold to be
considered a “structured psychosocial intervention”. If such a skill
were used as part of a clearly defined, consistent and evidence-
based package of psychological treatment, especially when
delivered by a demonstrably competent practitioner, it would then
be part of a “structured psychosocial intervention”. Examples of
structured psychosocial interventions could include four sessions
of family therapy, or a manualised relapse prevention package.
In this definition, psychosocial interventions are to be differentiated
from a number of other interventions:
• While psychosocial interventions may be delivered by a
keyworker, this activity is not part of the keyworking process
per se. The keyworker may provide a level of ongoing face-to-
face therapeutic support involving the use of some
psychological techniques. If keyworkers do not deliver
complete and consistent psychological treatment packages
as part of their work with individual clients, it does not
constitute a “structured psychosocial treatment”. For example,
a keyworker helping a client draw up a list of pros and cons is
not delivering a full motivational interviewing intervention,
merely using one technique commonly associated with the
approach. Where keyworkers do deliver a planned, structured
and coherent evidence-based psychosocial intervention (for
which they have received training and supervision) this is likely
to comprise a number of sessions and this constitutes a
structured psychosocial intervention.
• The difference between psychosocial interventions for problem
substance misuse and formal psychological therapies
targeting a client’s co-morbid mental health problems is that
the latter interventions are specialist psychological treatments
(such as cognitive-behaviour therapy for depression or anxiety,
cognitive-analytic therapy, dialectical behaviour therapy, or
schema-focused therapy for personality disorders) aimed
primarily at the non-drug psychological problem. Such
interventions should only be delivered by specialist
practitioners such as clinical and counselling psychologists,
suitably trained psychiatric staff or other specialist therapists
with relevant training, qualifications and supervision in the
therapy model being offered. This would be delivered as part
of the care plan but would not constitute a “structured
psychosocial intervention” for problem drug use itself
• Psychosocial interventions also differ from advice, information,
simple psycho-education or other low-threshold support,
which may be provided by a range of practitioners in a range
of treatment settings.
Settings: A range of community and residential services. Some
structured psychosocial interventions may be delivered as part of
the process of engaging and preparing clients for change and
during the “delivery” phase of the client’s treatment journey.
Therefore, they may be delivered in different settings for individuals
at different stages of their treatment journey. In prisons, structured
psychosocial interventions would generally be provided through
CARATs.
9.7 “Other structured treatment”
“Other structured treatment” describes a package of interventions
set out in a client’s care plan which includes as a minimum regular
planned therapeutic sessions with the keyworker or other drugs
worker. The care plan should address drug and alcohol misuse,
health needs, offending behaviour and social functioning. “Other
structured treatment” describes structured therapeutic activity not
covered under the alternative specific intervention categories set
out in Models of Care: Update 2006.
The creation of this “other” category of intervention reflects the
evidence base that drug treatment consisting of individually
tailored packages of care, in the context of a therapeutic
relationship, is beneficial. This intervention may be particularly
relevant for non-opiate drug misusers and clients who are
receiving criminal justice treatment interventions.
Clients in receipt of community prescribing interventions,
residential rehabilitation, inpatient treatment, structured day
programmes or structured psychosocial interventions should not
be additionally recorded as receiving “other structured treatment”.
Care-planned support usually provided by the keyworker is
integral to all such interventions anyway.
Most clients receiving “other structured treatment” will receive a
range of interventions to meet needs identified in their care plan.
These will involve a range of interventions to address their drug
misuse and support to address needs in other domains.
Examples of these may include: 
• A crack user who is receiving regular sessions with a
keyworker and attending “day care” sessions to address a
range of social and health-related needs
• An opiate user who has been through community
detoxification and is receiving ongoing support to maintain
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abstinence as part of the care plan (prior to referral on or
provision of aftercare arrangements), and is also receiving
harm reduction interventions and help to deal with health
needs
• An uncomplicated problem cannabis user who is receiving a
short period of care-planned regular brief interventions to deal
with problem cannabis use
• Clients who are not assessed as needing “structured
psychosocial interventions” for their problem drug use, but
who receive sessions with keyworkers to address their social
needs and offending behaviour.
“Other structured treatment” can describe regular sessions with a
keyworker, delivered in order to keep a client engaged in the
treatment system while they are waiting to start receiving another
care-planned intervention (e.g. GP prescribing), if the structured
interventions are outlined in an initial care plan following a triage
assessment.
Clients receiving “day care” rather than a structured “day
programme”, as part of a care plan, may be recorded as “other
structured treatment”. Day care is distinct from structured day
programmes, because it has a lower requirement to attend than
structured day programmes (usually 1–2 days). Some clients may
have a care plan that specifies regular attendance at day care
with regular sessions with keywork. As part of the care-planned
day care they may receive a range of interventions and support
including emotional and psychological support, educational and
life-skills work and related activities, advice and information, harm
reduction support, further assessment and subsequent referral to
alternative structured treatment. This may be particularly relevant
for clients who have co-existing mental health problems.
A client should not be recorded as receiving “other structured
treatment” if the interventions are not being delivered as part of a
care plan. It is also important to note that “other structured
treatment” requires a more rigorous approach to “keyworking”. As
good practice, keywork involves the building of a therapeutic
relationship with the client, which should include: 
• Following triage, drawing up an initial care plan if required to
address immediate needs (e.g. providing information and
advice on drug and alcohol misuse) 
• Harm reduction interventions
• Motivational interventions to enhance retention
• Developing and agreeing the care plan with the client and
ensuring implementation of the care plan – with interventions
relevant to each stage of the treatment journey and regular
care plan reviews.
Other structured treatment involves the delivery of a package of
structured interventions that are beyond the level that would be
required for Tier 2, but do fall into the other categories of
structured interventions described in this section.
Settings: Other structured treatment could take place in a wide
variety of different treatment settings, including settings that may
normally be known for delivering Tier 2 interventions.
9.8 Inpatient drug treatment 
Inpatient drug treatment interventions usually involve short
episodes of hospital-based (or equivalent) drug and alcohol
medical treatment. This normally includes 24-hour medical cover
and multidisciplinary team support for treatment such as:
• Medically supervised assessment
• Stabilisation on substitute medication
• Detoxification/assisted withdrawal from illegal and substitute
drugs and alcohol in the case of poly-dependence
• Specialist inpatient treatments for stimulant users 
• Emergency medical care for drug users in drug-related crisis.
The multidisciplinary team can include psychologists, nurses,
pharmacists, occupational therapists, social workers, and other
activity and support staff.
Inpatient drug treatment should be provided within a care plan
with an identified keyworker. The care plan should address drug
and alcohol misuse, health needs, offending behaviour and social
functioning.
Care-planned inpatient treatment programmes may also include a
range of additional provisions such as:
• Preparing the client for planned admission to inpatient
treatment (if this is not carried out by a suitably competent
community worker as part of the agreed care plan leading to
admission)
• Psychosocial interventions, including relapse prevention work
• Interventions to tackle excessive levels of drinking
• Appropriate tests or vaccination (if appropriate) for hepatitis B,
C and HIV
• Other harm reduction interventions
• Educational work
• Physical and mental health screening 
• Linking inpatient treatment to post-discharge care, which may
involve preparation for referral to residential rehabilitation or
community treatment, aftercare or other support required by
the client.
Inpatient drug treatment is an important intervention for enabling
adequate assessment of complex needs and for supporting
progression to abstinence.
It is very important to have effective discharge care planning, and
to ensure appropriate referrals to mainstream medical services
(e.g. liver clinic and psychiatric services) or social and community
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services (e.g. housing, legal advice, social services), as well as
harm reduction and relapse prevention advice as required.
Settings: The three main settings for inpatient treatment are: 
• General hospital psychiatric units
• Specialist drug misuse inpatient units in hospitals
• Residential rehabilitation units (as a precursor to the
rehabilitation programme). 
Research evidence has demonstrated that clients who receive
treatment in dedicated substance misuse units are more likely to
have better outcomes than those who receive treatment in
general psychiatric wards.
For further information and guidance on inpatient treatment, refer
to:
• Opiate detoxification in an inpatient setting (NTA, 2005)32
• SCAN Consensus Project 1: Inpatient Treatment of Drug and
Alcohol Misusers (forthcoming).
9.9 Residential rehabilitation 
Drug residential rehabilitation consists of a range of treatment
delivery models or programmes to address drug and alcohol
misuse, including abstinence orientated drug interventions within
the context of residential accommodation.
Residential rehabilitation programmes should include care
planning with regular keyworking with an identified keyworker. The
care plan should address drug and alcohol misuse, health needs,
offending behaviour and social functioning.
There is a range of residential rehabilitation services, which
include:
• Drug and alcohol residential rehabilitation services whose
programmes to suit the needs of different service users.
These programmes follow a number of broad approaches
including therapeutic communities, 12-Step programmes and
faith-based (usually Christian) programmes
• Residential drug and alcohol crisis intervention services (in
larger urban areas)
• Inpatient detoxification directly attached to residential
rehabilitation programmes
• Residential treatment programmes for specific client groups
(e.g. for drug-using pregnant women, drug users with liver
problems, drugs users with severe and enduring mental
illness). Interventions may require joint initiatives between
specialised drug services (Tier 3 or 4, depending on local
arrangements) and other specialist inpatient units
• Some drug-specific therapeutic communities and 12-Step
programmes in prisons
• “Second stage” rehabilitation in drug-free supported
accommodation where a client often moves after completing
an episode of care in a residential rehabilitation unit, and
where they continue to have a care plan, and receive keywork
and a range of drug and non-drug-related support
• Other supported accommodation, with the rehabilitation
interventions (therapeutic drug-related and non-drug-related
interventions) provided at a different nearby site(s).
Residential rehabilitation programmes normally combine a mixture
of group work, psychosocial interventions and practical and
vocational activities. These components are also used in specialist
residential programmes for particular client groups (e.g. parent
and child programmes).
Clients usually begin residential rehabilitation after completing
inpatient detoxification. Sometimes the detoxification will take
place on the same site as the rehabilitation programme, to
enhance continuity of care. Prior to starting the rehabilitation
programme, the client should be supported by their keyworker (or
other substance misuse professional) to prepare for admission, so
as to minimise disengagement and maximise benefit, but there
may also be preparation input from the rehabilitation service.
Settings: The main settings for residential treatment are purpose-
built or refurbished units, which may be freestanding or converted
residential houses. They vary in size, and clients are received from
a wide (often national) catchment area. Some residential units
have medical facilities for inpatient pre-residential programme
detoxification treatment.
9.10 Aftercare 
Aftercare, as described in Models of Care, is a package of
support that is planned with the client to support them when they
leave structured treatment. The aim of aftercare is to sustain
treatment gains and further develop community reintegration.
Aftercare may include drug-related interventions such as open
access relapse prevention or harm reduction. It may also include
non-drug-related support such as housing, access to education,
and generic health and social care. It is important to note that
aftercare is not necessarily what a client receives after leaving Tier
4 treatment or prison, as they may still have an active care plan,
involving community interventions. Only once the client’s care plan
is complete do they enter planned aftercare.
During a period of care-planned treatment, clients will receive a
range of interventions to address their drug and alcohol-using
behaviour and interventions to target non-substance use domains
of functioning (e.g. housing, family support). Some of these
interventions will come to an end when the care plan comes to an
end, but some may need to continue.
As long as clients have an active care plan they are considered to
be “in treatment”. When their care plan with the treatment
provider comes to an end, they may continue to receive a range
of services that they were receiving as part of the care plan, and
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in this context, these will be deemed to be aftercare. These
include drug-related support and non-drug-related support.
There is a need to ensure the client has access to support
pathways (e.g. for housing and training) If links to all appropriate
support services are not already in place during a client’s care-
planned treatment, drug treatment agencies should assist the
client to make these links before their treatment comes to an end.
The keyworker or service should work closely with local agencies
providing aftercare and support services to enable all necessary
support to be in place in time for the client leaving treatment.
During the completion or exit phase of treatment, an aftercare
plan should be drawn up by the keyworker and agreed with the
client, based on assessment of ongoing support needs, and
informed where possible by related professionals (e.g. housing
and CJIT workers).
The aftercare plan should include measures that cover possible
relapse and ensure swift access back to treatment if required. The
aftercare plan must be passed from the drug treatment agency to
the agencies responsible for delivering the aftercare, and key staff
in this agency should ensure that the plan is implemented and
clients receive what is outlined in the aftercare plan.
Drug-related support could include open-access relapse
prevention, mutual support groups (e.g. AA/NA or equivalent user-
led groups), and advice and harm reduction support. In addition a
range of open-access and low-threshold interventions should be
available to provide specific interventions to people who have
completed treatment, but who may want or need to have
occasional non-care-planned support.
Non-drug-related support can cover a range of issues such as
access to housing, supported accommodation, relationship
support, education and training, support to gain employment, and
parenting and childcare responsibilities. In addition, women’s
services, peer mentor programmes and other social and activity
groups can form elements of non-drug-related support.
Further details on how aftercare provision has been progressed
can be found in Developing Peer Led Support For Individuals
Leaving Substance Misuse Treatment (2005),54 which gives an
outline of emerging themes and findings from five peer-led
support projects, and the Addaction Aftercare Consultation 2005:
The Service User Perspective,55 which builds upon the findings of
Addaction’s national survey of drug and alcohol treatment
providers, published in 2004. Other useful references on aftercare
provision include:
• The Addaction National Aftercare Research Project Year 3
(2006)56
• The 24/7 client single point of contact – Case Examples of
Good Practice (Home Office, 2005)57
• Promoting Practice between DAT partnerships and Education
Training and Employment provision for Drug Interventions
Programme clients (Home Office, 2006)58
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